

University of California, San Francisco

CURRICULUM VITAE

Name: Richard Charles Kennedy Jordan, DDS, MSc, PhD, FRCD(C), FRCPath

Position: Professor, Step 5
Orofacial Sciences
School of Dentistry

Address: 1701 Divisadero Street Room 280
University of California
San Francisco CA 94115
Voice: 415-353-7550
Fax: 415-353-7553
Email: Richard.Jordan@ucsf.edu
Web: www.dermpath.ucsf.edu

EDUCATION

1981 - 1982	University of Western Ontario; Science	B.Sc. (not conferred, entry to Dentistry)	Chemistry
1982 - 1986	University of Toronto; Dentistry	D.D.S.	Dentistry (magna cum laude)
1988 - 1992	University of Toronto; Dentistry	Dipl. Oral Pathol. Med.	Oral Pathology & Oral Medicine
1990 - 1992	University of Toronto; Dentistry	M.Sc.	Oral Pathology
1992 - 1995	University of London; Medicine	Ph.D.	Experimental Pathology

LICENSES, CERTIFICATION

1986	Ontario Royal College of Dental Surgeons of Ontario Dental license #D10833
1991	Ontario Royal College of Dental Surgeons of Ontario Specialist certificate #M10833
1993	Canada Royal College of Dentists Fellow in Oral Pathology
1997	US American Board of Oral & Maxillofacial Pathology Diplomate
1998	US American Board of Oral Medicine Diplomate #381
1998	Canada Royal College of Dentists Fellow in Oral Medicine
2001	California Dental Board of California Special Permit #SP196
2001	US Drug Enforcement Agency Certificate #BJ7498694

2002	California Department of Health Services Laboratory Director license #DRO 003
2004	British Columbia College of Dental Surgeons of British Columbia Dental license #5697
2004	British Columbia College of Dental Surgeons of British Columbia Specialist in Oral Pathology #5697
2007	UK Royal College of Pathologists Fellow
2009	California Dental Board of California Dental license #58144
2009	Washington Department of Health Dental license #DE60086482

PRINCIPAL POSITIONS HELD

1995 - 2000	University of Toronto	Assistant Professor	Dentistry
2000 - 2000	University of Toronto	Associate Professor	Dentistry
2000 - 2001	University of California San Francisco	Associate Adjunct Professor	Stomatology
2001 - 2005	University of California San Francisco	Associate Professor	Stomatology
2005 - 2006	University of California San Francisco	Associate Professor	Orofacial Sciences
2006 - present	University of California San Francisco	Professor (tenured)	Orofacial Sciences
2006 - present	University of California San Francisco	Professor	Pathology, School of Medicine
2011 - present	University of California San Francisco	Professor	Radiation Oncology

OTHER POSITIONS HELD CONCURRENTLY

1995 - 2000	Sunnybrook & Women's College Hospital	Assistant Professor	Pathology
1995 - 2000	Sunnybrook & Women's College Hospital	Assistant Professor	Dentistry
1995 - 2000	Sunnybrook & Women's College Hospital	Assistant Professor	Otolaryngology
2000 - 2000	University of Toronto	Associate Professor	Otolaryngology

2000 - 2000	University of Toronto	Associate Professor	Laboratory Medicine
2000 - 2000	Sunnybrook & Women's College Hospital	Associate Professor	Dentistry
2000 - 2000	Sunnybrook & Women's College Hospital	Associate Professor	Pathology
2000 - 2006	University of California San Francisco	Associate Professor	Pathology
2000 - present	UCSF Medical Center	Attending Staff	Dentistry
2000 - 2009	UCSF Comprehensive Center	Program leader, clinical	Oral/Head& Neck Oncology
2004 - present	UCSF Oral Pathology Laboratory	Laboratory Director	Orofacial Sciences
2005 - 2012	Clinical & Translational Sciences PhD program	Director	Graduate School
2005 - 2006	Oral & Craniofacial Sciences Graduate Program	Vice Chair	School of Graduate Studies
2006 - 2009	Oral & Craniofacial Sciences Graduate Program	Chair	Graduate Division
2008 - 2013	Executive committee, Training in Clinical Research Program (TICR)	Member	School of Medicine
2011 - present	NRG Oncology Biospecimen Bank	Director	NRG Oncology

HONORS AND AWARDS

1981	Entrance Scholarship	University of Western Ontario
1982	Senate Scholarship, University of Western Ontario	University of Western Ontario
1985	Wroblewski Award for highest standing in Paedodontics	University of Toronto
1985	Mosby Prize in Orthodontics	University of Toronto
1985	Murray Cornish Scholarship for highest standing in Oral Pathology	University of Toronto
1986	Xi Xsi Phi Fraternity award for highest academic standing	Xi Xsi Phi
1986	Dental Student's Society award for academic excellence	University of Toronto
1986	Dean's Honour List	University of Toronto

1991	Magder Fellowship	Canadian Reference Centre for Tumour Pathology
1991	Ontario Graduate Scholarship	Government of Ontario
1991	University of Toronto Open Fellowship	University of Toronto
1991	Fellowship	Canadian Fund for Dental Education
1992	MENSA Canada Fellowship	MENSA
1992	Research Fellowship (ranked 2nd out of 305 in competition list)	Medical Research Council of Canada
1994	International Association of Oral Pathology (IAOP) Prize Competition: Best Abstract at Conference	International Association of Oral Pathology
1995	International Association for Dental Research (IADR) Experimental Pathology: Best Abstract	International Association for Dental Research
1998	Ministry of Health Career Scientist Award (1998-2004) (terminated early due to relocation to the USA)	Ontario Ministry of Health
2005	Distinguished Teaching Award	UCSF School of Dentistry
2005	Outstanding Teacher Award, Department of Orofacial Sciences, School of Dentistry, UCSF	
2007	Fellow	Royal College of Pathologists (FRCPath)
2007	Mentor of the year award	UCSF School of Dentistry
2011	Fellow	American College of Dentists

KEYWORDS/AREAS OF INTEREST

MAJOR AREAS OF EXPERTISE

Problem solving, leadership, critical analysis, strategic planning, teambuilding and teamwork, innovation, communication and implementation.

ACADEMIC EXPERTISE

Medical & dental sciences including: pathology, oral medicine, laboratory medicine, molecular medicine, cancer biology, graduate education

CLINICAL EXPERTISE

Diagnostic surgical pathology with expertise in lymphoma and soft tissue tumor diagnosis including advanced diagnostic & molecular methods. Clinical oral medicine including mucosal disease diagnosis and management.

ADMINISTRATIVE & LEADERSHIP

Laboratory governance; Academic governance; Hospital governance; DDS, PhD and post-doctoral training in medical and dental sciences; Conference and symposia organization.

CLINICAL ACTIVITIES

CLINICAL ACTIVITIES SUMMARY

I am a pathologist-scientist board certified in both oral & maxillofacial pathology and oral medicine with specialized expertise in the diagnosis and pathology of oral/head and neck diseases and tumors. Currently, I serve as an expert oral & maxillofacial pathologist in the UCSF Dermatopathology & Oral Pathology Service where I diagnose and report on oral/head and neck biopsy and excision specimens from surgeons, dentists and other clinicians from UCSF and from the community. The range of diseases that are reported is wide and includes common inflammatory skin lesion to rare and difficult melanomas and other pigmented lesions. Typically I report 150 cases per week in addition to challenging cases sent by pathologists for second opinion. This clinical service is important not only to the patient but it is also intertwined and informs my investigational studies in the biology of oral diseases. One half day per week I perform these service activities in oral pathology at a multiheaded microscope to teach medical students, residents and fellows in dermatology, pathology and dentistry about mucosal and head and neck pathology and integrate these findings into clinical care. In addition, I attend teaching conferences where difficult cases are discussed for educational purposes. UCSF pathologists frequently consult with me on difficult head and neck pathology and I have gained immeasurable satisfaction knowing that the ultimate beneficiary of my clinical skills is a patient.

CLINICAL SERVICES

- 2000 - present Director, Oral Pathology Section UCSF Dermatopathology & Oral Pathology Service: In 2013 I worked with Dr. P. Leboit and Dr. T. McCalmont to merge the dermatopathology and oral pathology services at UCSF into one organization, the UCSF Dermatopathology and Oral Pathology Service. This is the largest academic dermatopathology service in the US with the oral pathology division reporting on specimens for oral surgeons, dentists and other medical professionals from the US and internationally. Currently I report the vast majority of the over 7500 oral/head and neck specimens accessioned each year. The service also provides approximately 800 consultations for general and oral pathologists at UCSF and outside for difficult and unusual head and neck pathology. 5 days per week
- 2000 - present Attending Oral & Maxillofacial Pathologist, UCSF Medical Center: I attend this service as an oral & maxillofacial pathologist 12 months of the year. I review biopsies taken at the UCSF Medical Center and provide outside consultation cases for patients who are referred to UCSF Medical Center for treatment. There are about 500 such cases a year. 5 days per week

2000 - present	UCSF Comprehensive Cancer Center Head and Neck Tumor Board: I attend and participate in the UCSF Head and Neck Tumor Board. This is held weekly and I am responsible for presenting and discussing the pathology of cases reviewed that week.	one half day per week
2000 - present	UCSF Department of Pathology: I review a large proportion of the difficult and challenging oral, head & neck and salivary gland pathology that is seen in the Department of Pathology. This service is provided on an ad hoc basis to the general surgical pathologists and amounts to several hundred cases a year.	variable commitment, as needed
2000 - present	Oral Medicine Clinic: I provide consultations and assistance to clinicians in the Oral Medicine clinic for difficult or challenging clinical cases 12 months of the year. The case load averages 1 or 2 patients per month. I also see patients at the UCSF Medical Center when requested for various oral lesions.	variable commitment, as needed

PROFESSIONAL ACTIVITIES

MEMBERSHIPS

- 1989 - present Canadian Academy of Oral Pathology
- 1992 - present International Association of Oral Pathologists
- 1993 - present British Society of Oral Pathology
- 1994 - present British Society for Dental Research
- 1995 - present International Association for Dental Research
- 1996 - present Canadian Dental Association
- 1997 - present American Academy of Oral and Maxillofacial Pathology
- 1997 - present American Association for Cancer Research
- 1997 - present American Academy of Oral Medicine
- 1999 - present United States and Canadian Academy of Pathology
- 2000 - present American Association for Dental Research
- 2002 - present American Society of Investigative Pathology

SERVICE TO PROFESSIONAL ORGANIZATIONS

- 1992 - 1994 Canadian Academy of Oral Pathology Chair, Publicity and Public Relations

1995 - 1995	International Association of Oral Pathology	Oral Cancer Plenary Symposium. Session organizer and moderator.
1995 - 2000	Canadian Academy of Oral Pathology	Secretary-Treasurer
2001 - 2002	International Association for Dental Research	Member at large, Oral Pathology and Medicine group
2002 - 2002	American/International Association for Dental Research	Organizer. Special Symposium.
2008 - 2008	International Association of Oral Pathology & American Academy of Oral & Maxillofacial Pathology Joint meeting	Chair, Local organizing committee
2008 - 2014	Radiation Oncology Therapy Group	Member several steering committees including Biorepository and Pathology committees
2008 - present	National Cancer Institute Group Banking Committee	Member and Vice Chair including membership on 4 subcommittees
2014 - present	NRG Oncology	Member several steering committees including Biorepository and Pathology committees

SERVICE TO PROFESSIONAL PUBLICATIONS

1995 - present	Journal of the Canadian Dental Association (Journal Reviewer, 5 papers in past 5 years)
1995 - present	Journal of Cell and Bone Biology (editorial board)
1995 - present	Annals of the Rheumatic Diseases (Journal Reviewer, 3 papers in past 5 years)
1996 - present	Journal of Oral Pathology & Medicine (Journal Reviewer, 5 papers in past 5 years)
1996 - present	Oral Diseases (Journal Reviewer, 5 papers in past 5 years)
1996 - present	Oral Oncology (Journal Reviewer, 30 papers in past 5 years)

- 1996 - present Oral Surgery Oral Pathology Oral Medicine (Journal Reviewer, 10 papers in past 5 years)
- 1998 - present American Journal of Pathology (Journal Reviewer, 3 papers in past 5 years)
- 1999 - present Oral Oncology (editorial board)
- 1999 - present Modern Pathology (Journal Reviewer, 8 papers in past 5 years)
- 2002 - present Archive of Oral Biology (editorial board)
- 2002 - present International Journal of Cancer (Journal Reviewer, 4 papers in past 5 years)
- 2002 - present Clinical Cancer Research (Journal Reviewer, 5 papers in past 5 years)
- 2003 - present Cancer Letters (Journal Reviewer, 5 papers in past 5 years)
- 2004 - present Oral Biosciences & Medicine (Journal Reviewer, 5 papers in past 5 years)
- 2004 - present American Journal of Dermatopathology (Journal Reviewer, 2 papers in past 5 years)
- 2005 - present Carcinogenesis (Journal Reviewer, 2 papers in past 5 years)
- 2005 - present Oncogene (Journal Reviewer, 2 papers in past 5 years)
- 2005 - present Journal of Histochemistry & Cytochemistry (Journal Reviewer, 5 papers in past 5 years)
- 2009 - present BMC Cancer (Journal Reviewer, 1 paper per year)
- 2009 - present Journal of Cutaneous Pathology, (editorial board)
- 2011 - present Oral Surgery, Oral Medicine, Oral Pathology (editorial board)

INVITED PRESENTATIONS - INTERNATIONAL

- | | | |
|------|---|-----------------|
| 1997 | Asia-Pacific Head and Neck Congress, Mumbai, India. December 1997 | Invited speaker |
| 1996 | International Association of Oral Pathology Congress; Toronto, Canada, July 1996 | Invited speaker |
| 2004 | University of California San Francisco 11th annual Oral & Maxillofacial symposium. January 2004 | Invited speaker |
| 2004 | American Association of Oral & Maxillofacial Surgeons annual meeting. October 2004 | Invited speaker |
| 2005 | XIII Brazilian Congress of Estomatology. Florianopolis Brasil. Oral Pathology. July 2005 | Invited speaker |
| 2006 | 13th International Congress on Oral Pathology and Medicine, Brisbane Australia. June 2006 | Plenary speaker |
| 2009 | International Association of Oral Pathology Congress; Seoul Korea August 2009 | Plenary speaker |

2011	Royal College of Pathologist North American chapter founding meeting. May 2011	Plenary speaker
2011	1st Annual Inaugural Symposium of Human Papilloma Virus, June 11- June 13, 2011 Beijing, China	Invited speaker
2012	Pathology Society of Great Britain & Northern Ireland, Sheffield, UK July 2012	Plenary speaker
2015	International Society of Dermatopathology meeting, San Francisco CA, March	Invited speaker
2015	Dermatopathology in Paradise, Maui, HI, October 2015	Invited speaker

INVITED PRESENTATIONS - NATIONAL

2003	University of California San Francisco - Oral & Maxillofacial Surgery Hawaii Symposium CPC	Invited Speaker
2013	American Society of Dermatopathology. Washington DC. "HPV and head and neck cancer"	Plenary Speaker
2014	American Society of Dermatopathology. Washington DC. "Unusual oral pathology"	Plenary speaker
2016	American Society of Dermatopathology. Chicago IL. "Oral pathology, unusual and challenging cases"	Invited speaker
2016	Eastern Society of Teachers of Oral Pathology (ESTOP) and Western Society of Teachers of Oral Pathology (WESTOP) joint meeting. "National co-operative cancer groups"	Plenary speaker
2016	American Society of Dermatopathology. Chicago IL. "Oral pathology slide review sessions 303 & 304"	Invited speaker
2017	American Academy of Dermatology. Ft Lauderdale FL. "Oral Pathology: review of clinical and pathology cases"	Plenary speaker
2017	US and Canadian Academy of Pathology Interactive Microscopy. "Dermatopathology in the Desert".	Invited speaker
2017	American Society of Dermatopathology. Baltimore MD. "Oral pathology slide review sessions 303 & 304"	Invited speaker/session chair
2018	American Society of Dermatopathology. Baltimore MD. "Oral pathology slide review sessions 207 & 405"	Invited speaker/session chair
2018	Colorado Society of Clinical Pathology	Invited speaker/plenary speaker

INVITED PRESENTATIONS - REGIONAL AND OTHER INVITED PRESENTATIONS

1990	Ontario Dental Association Convention; Toronto, Ontario, Canada November 1990	Plenary speaker
1991	University of Toronto continuing education course; Toronto, Canada: March 1991	Plenary speaker
1991	University of Toronto, comprehensive dentistry program; Toronto, Canada: March 1991	Plenary speaker
1992	Ontario Association of Endodontists annual meeting; Toronto Canada: May 1992	Plenary speaker
1994	Eastman Dental Institute. Invited Speaker Series. London, UK: February 1994	Invited speaker
1994	Royal Postgraduate Medical School. Surgical science series. Hammersmith, UK: March 1994	Invited speaker
1994	Toronto Western Hospital. Rheumatology and immunology seminars. Toronto, Canada: April 1994	Invited speaker
1994	Kanazawa Medical University invited speaker series. Kanazawa, Japan: May 1994	Invited speaker
1994	Sunnybrook Health Science Centre, Toronto, Canada. September 1994	Invited speaker
1995	Toronto Dermatologic Society. Toronto, Canada: 17th postgraduate dermatologic seminar; October 1995	Invited speaker
1995	Head and neck oncology research meeting. Mount Sinai Hospital. Toronto, Canada: November 1995	Invited speaker
1996	Xi Xsi Phi Continuing Dental Education Series; Toronto, Canada: January 1996	Plenary speaker
1996	Department of Otolaryngology, City-wide rounds, University of Toronto. Toronto Canada: February 1996	Invited speaker
1996	Continuing Education Series. Sunnybrook Health Science Centre. Dentistry for the Geriatric Population. September 1996	Invited speaker
1996	Toronto East Dental Society Meeting. November 1996	Plenary speaker
1996	North York Public Board of Health. November 1996 (Invited speaker)	
1997	Faculty of Dentistry, University of Michigan, Ann Arbor, USA: January 1997	Invited speaker
1997	Hamilton-Wentworth District Dental Hygienists Society. April 1997	Plenary speaker

1997	Department of Pathology, University of Western Ontario. London, Canada: April 1997	Invited speaker
1997	University of California at San Francisco, San Francisco, USA: July 1997	Invited speaker
1997	Kitchener and Waterloo District Dental Society. Kitchener, Canada: November 1997	Invited speaker
1997	Eastman Dental Institute, University College, London UK. December 1997	Invited speaker
1998	Niagara District Dental Hygienists Society. April 1998	Invited speaker
1998	Peterborough and District Dental Society. May 1998	Invited speaker
1998	Ohio State University. July 1998	Invited speaker
1998	Toronto-Sunnybrook Regional Cancer Centre. Oncology Grand Rounds. October 1998	Invited speaker
1998	University of Toronto, Faculty of Medicine Otolaryngology Alumni Day. November 1998	Invited speaker
1998	Toronto-Sunnybrook Regional Cancer Centre. Radiation Oncology Grand Rounds. November 1998	Invited speaker
1999	University of California San Francisco. School of Dentistry. February 1999	Invited speaker
1999	Toronto-Sunnybrook Regional Cancer Centre. April 1999	Invited speaker
2000	University of Toronto Dermatology rounds. February 2000	Invited speaker
2000	Department of Dentistry, SWCHSC. February 2000	Invited speaker
2000	Toronto-Sunnybrook Regional Cancer Centre. May 2000	Invited speaker
2000	University of California San Francisco pathology residents' lecture series. May 2000	Invited speaker
2000	University of California San Francisco. Oral & Maxillofacial Surgery Grand Rounds. August 2000	Invited speaker
2000	University of California San Francisco Brown Bag lecture series. September 2001	Invited speaker
2002	California Association of Oral and Maxillofacial Surgeons meeting. May 2002	Invited speaker
2002	University of California San Francisco. Graduate students lecture series. May 2002	Invited speaker
2002	Western Society of Teachers of Oral Pathology annual meeting. September 2002	Plenary speaker
2004	University of Toronto. Invited lecturer. September 2004	Invited speaker

2004	University of Washington, Distinguished Speakers series. December 2004	Invited speaker
2006	University of California San Francisco. Oral & Maxillofacial Surgery; Craniofacial Sciences Lecture series. February 2006	Invited speaker
2006	University of California San Francisco, Current Issue in Pathology. CME. June 2006	Invited speaker
2007	University of California San Francisco, Oral & Maxillofacial Surgery/Pathology. CME. October 2007	Invited speaker
2009	University of California San Francisco. Graduate students lecture series. February 2009	Invited speaker
2009	University of California San Francisco. Orofacial Sciences Grand Rounds. March 2009	Invited speaker
2009	San Mateo Dental Society. April 2009	Invited speaker
2009	Marin County Dental Society. September 2009	Invited speaker
2010	San Mateo Dental Society. May 2010	Invited speaker
2011	University of California San Francisco, Oral Surgery CME. February 2011	Invited speaker
2011	University of California San Francisco, Otolaryngology/Head & Neck Surgery Grand Rounds. April 2011	Invited speaker
2011	San Mateo Dental Society. May 2011	Invited speaker
2011	Diablo Study Club. November 2011	Invited speaker
2012	East Bay Study Group September 2012	Invited speaker
2013	UCSF Otolaryngology/ENT Grand Rounds November 2013	Invited speaker
2013	UCSF Oral & Maxillofacial Surgery CME February 2013	Invited speaker
2014	UCSF Oral & Maxillofacial Surgery CME January 2014	Invited speaker
2014	California Society of Pathology December 2014	Invited speaker
2015	California Society of Pathology December 2015	invited speaker
2015	UCSF Dermatology Grand Rounds August 2015	Invited speaker
2016	Pacific Coast Society of Prosthodontics. July 2016	Plenary speaker
2017	Current Issues in Pathology May 2017	Invited Speaker
2017	California Society of Pathology December 2017	Invited speaker
2018	Colorado Society of Clinical Pathology. Stars in the Mountain Annual meeting. Vail CO September 2018	Invited speaker

2018	Oregon Society of Pathology annual meeting. Portland OR. December 2018	Invited speaker/plenary speaker
------	--	---------------------------------

CONTINUING EDUCATION AND PROFESSIONAL DEVELOPMENT ACTIVITIES

Requirements for continued licensure and certification by the American Board of Oral and Maxillofacial Pathology have been met.

Requirements for continued licensure and certification by the American Board of Oral Medicine have been met.

Requirements for continued licensure and certification for Dental Board of California Dental have been met.

Requirements for continued licensure and certification for Laboratory Director's license in the State of California, Department of Health and Human Services have been met

Requirements for continued licensure and certification for Washington State Dental Board

Requirements for continued licensure and certification by College of Dental Surgeons of British Columbia have been met

2004	Leadership Skill Training. University of California San Francisco, CA, May-June
2005	Leadership Skill Training. University of California San Francisco, CA, April-June
2006	Management training. University of California San Francisco, CA. September-January

GOVERNMENT AND OTHER PROFESSIONAL SERVICE

1995 - 1995	University of Manchester	External reviewer for promotion of N. Thakker to Senior Lecturer
1996 - 1999	Medical Research Council of Canada	Ad hoc reviewer
2002 - present	National Institutes of Health/National Cancer Institute Special Emphasis panel	Ad hoc reviewer
2002 - present	National Institutes of Health/National Institute of Dental & Craniofacial Research	Ad hoc reviewer Oral Biology & Medicine-1 study section
2004 - present	Michael Smith Foundation for Health Research. Province of British Columbia	Reviewer

2005 - 2005	University of Manchester	External reviewer for promotion to Senior Lecturer of R. Oliver
2006 - 2006	University of Queensland	External reviewer for promotion to Senior Lecturer of C. Farah
2007 - present	Garnett Passe and Rodney Williams Memorial Foundation	Reviewer
2010 - present	Radiation Therapy Oncology Group Head and Neck Steering committee	Member
2011 - present	National Cancer Institute NCTN Group Banking Steering committee	Member
2011 - present	Radiation Therapy Oncology Group Steering committee	Member
2014 - 2015	Cancer Care Ontario	Expert consultant head and neck treatment protocol guidelines
2015 - present	National Cancer Institute NCTN Group Banking Committee	Vice Chair

UNIVERSITY AND PUBLIC SERVICE

SERVICE ACTIVITIES SUMMARY

ADMINISTRATION & LEADERSHIP, UCSF:

2009-2013 Associate Dean for Research

Senior management team member of School of Dentistry. Oversight of research and graduate affairs in the School of Dentistry. Represents the Dental School on matters of research within the UCSF campus, and with appropriate organizations nationally and internationally. Liaison with NIDCR and other extramural agencies and professional groups maintain the school's overall success in fulfilling its research mission. Oversight of the School's Office of Graduate and Research Affairs (OGRA) including budget, development fundraising activities, staff supervision and fund raising. Responsible for the Graduate Group in Oral and Craniofacial Sciences, the OCS PhD and MS, the DDS/PhD, DDS/MCR, DDS/MS and all training grants. Annual budget of the OGRA office is approximately \$700,000 per year.

2003-now Chair, Division of Oral Pathology, Medicine & Radiology

Responsible for all aspects of Division leadership, direction and financial oversight. The Division is responsible for all undergraduate, graduate and post-graduate teaching in Oral Medicine, Oral Pathology and Oral Radiology. Patient treatment clinics take place in the Oral Medicine Clinic and the Sjogren's syndrome clinic. There is also an Oral Pathology Biopsy Laboratory (I also serve as Director). I have direct management oversight and fiscal accountability for a clinical services budget of approx. \$1.6 million per year. Basic, translational and clinical research occurs in several areas including oral AIDS, racial disparity and access to care, Sjogren's syndrome and oral cancer. Grant support within this Division totals approximately \$4 million per year.

2012-2017 Director, Oral & Maxillofacial Pathology residency

I developed, submitted and received approval from the Commission on Dental Accreditation a 3-year training program in Oral & Maxillofacial Pathology. This GME supported program will intake its first resident in July 2013. Closing integrated with other training programs (anatomic pathology, dermatopathology, clinical pathology, oral medicine) this education pathway will train the next leaders in the field of oral & maxillofacial pathology. One candidate graduated successfully from the program (Dr. Kyle Jones) who is now a UCSF faculty member. Due to a weak demand by candidates the program was closed in 2017.

2016-now Director AIDS Specimen Bank (ABS)

This is the largest campus-wide biorepository at UCSF. The ASB Core currently provides its biorepository services to UCSF HIV investigators who are supported by several NIH institutes including NIAID, NIDA, NIDCR, NCI, and NCCAM. The ASB Core participates in all CFAR planning and supports international as well as domestic research studies.

UNIVERSITY SERVICE

UC SYSTEM AND MULTI-CAMPUS SERVICE

2008 - 2009	Search committee for UCSF Chancellor	Member
-------------	--------------------------------------	--------

UCSF CAMPUSWIDE

2001 - present	Academic Senate, Ad hoc faculty reviews (1 in 2009, 1 in 2008, 1 in 2007, 1 in 2006, 2 in 2005, 2 in 2004, 2 in 2003)	Ad hoc reviewer
2001 - 2007	Oral-Head and Neck Oncology Program (OHNO), UCSF Comprehensive Cancer Center	Program leader, clinical
2003 - 2004	Chancellor's Council, UCSF	Member
2004 - 2007	Academic Senate, Committee on Rules and Jurisdiction.	Member
2004 - present	UCSF Tissue Oversight committee, UCSF Comprehensive Cancer Center	Member
2004 - 2008	Grant review panel, Stewart Research Fund, UCSF Comprehensive Cancer Center	Member
2005 - 2012	Steering committee, Oral & Craniofacial Sciences Graduate Program	Member
2005 - 2012	OCS- Clinical Translational Sciences Training (OCS-CTST)	Director
2005 - 2006	Senior Leadership Group, Clinical and Translational Sciences Award (CTSA) program	Member
2006 - 2009	UCSF Academic Senate, Committee on Committees	Member
2006 - 2009	Mentoring and Education program, Clinical & Translational Sciences Institute (CTSI)	Assistant Director
2006 - 2009	Oral & Craniofacial Sciences Graduate program	Chair
2007 - 2010	Industry Alliance Coordinating Committee	Member

2008 - 2014	Advisory board, Pathways in Careers in Clinical Translational Research (PACCTR)	Member
2008 - 2014	Scientific review & selection committee UCSF Clinical & Translational Sciences Institute (CTSI) KL2 program	Member
2010 - 2011	CTSI Biospecimen Resource Task Force	Member
2010 - 2013	Operational Excellence Faculty Oversight Committee	Member
2010 - 2011	Clinical Research Infrastructure Task Force	Member
2010 - 2011	Decade of Human Biology Task Force. Clinical & Translational Research	Member
2011 - 2012	Long Range Development Plan Committee - Research	Member
2012 - 2014	UCSF Executive Space Committee	Member
2012 - 2013	UCSF Biospecimen Banking Committee	Member
2016 - 2016	Ad hoc committee appointed by Vice Chancellor Academic Affairs to investigate faculty misconduct	Member

SCHOOL OF MEDICINE

2006 - 2007	Department of Otolaryngology/Head & Neck Surgery faculty search committee	Member
2014 - present	Dermatopathology fellowship selection committee	Member
2015 - 2015	Department of Pathology Faculty search in head and neck pathology	Member
2015 - 2016	Department of Otolaryngology Head and Neck Surgery search for faculty member	Member

SCHOOL OF DENTISTRY

2001 - present	Academic Actions Committee	Member
2002 - 2002	Search committee, Department of Oral & Maxillofacial Surgery	Member
2003 - 2004	Faculty Council	Member
2004 - 2005	Dean's Creativity Fund review panel	Member
2003 - present	Research & Clinical Excellence committee	Member
2004 - present	Student status committee	Member
2005 - 2006	Search committee, Endodontics, Department of PRDS	Member
2006 - 2011	Search committee, Chair, Department of PRDS	Member
2007 - 2008	Post graduate education executive committee	Chair
2008 - 2009	Qualifying committee, PhD candidate Aditi Bhattacharya	Member

2009 - 2009	Qualifying committee, PhD candidate Thaddeus Connelly	Member
2011 - 2012	Search committee, Oral & Maxillofacial Surgery faculty	Member
2012 - present	School of Dentistry compensation plan committee	Member
2013 - present	Department of Orofacial Sciences Oral Medicine residency selection committee	Member
2016 - present	Academic Planning & Budget committee	Member

DEPARTMENTAL SERVICE

2000 - 2000	Department of Orofacial Sciences	Member, Staff Appreciation Award committee
2000 - 2000	Department of Orofacial Sciences	Chair, Search committee for Oral Medicine faculty position
2003 - present	Division of Oral Pathology, Oral Medicine, Oral Radiology, Department of Orofacial Sciences	Chair
2003 - 2014	Department of Orofacial Sciences	Vice Chair
2004 - 2004	Department of Orofacial Sciences	Chair, Search committee for Oral Pathology faculty position
2004 - 2005	Department of Orofacial Sciences	Member, Compensation Plan committee
2005 - 2005	Department of Orofacial Sciences	Chair, Search committee for Division Chair for Orthodontics
2005 - 2005	Department of Orofacial Sciences	Chair, Working group on Oral Radiology
2005 - 2006	Department of Orofacial Sciences	Chair, Search committee for faculty position in Orthodontics
2008 - present	Department of Orofacial Sciences	Chair, Search committee for faculty position in Oral Medicine

2008 - 2009	Department of Orofacial Sciences	Member, Search committee for Chair of Division of Orthodontics
2009 - 2010	Department of Orofacial Sciences	Chair, Search committee for Chair of Division of Orthodontics
2009 - 2010	Department of Orofacial Sciences	Chair, Search committee for faculty position in Oral Pathology
2016 - 2017	Department of Orofacial Sciences	Member search committee for Oral Medicine faculty

COMMUNITY AND PUBLIC SERVICE

2008 - 2014	Radiation Therapy Oncology Group Head and Neck Cancer committee	Member/Lead pathologist
2008 - 2014	Radiation Therapy Oncology Group Research Planning committee	Member
2008 - present	Radiation Therapy Oncology Group Foundation Executive Board	Member
2012 - present	National Cancer Institute Group Banking Committee	Vice Chair
2014 - present	NRG Oncology Head and Neck committee	Member/Lead pathologist
2014 - present	NRG Oncology Research Strategy Committee	Member
2014 - present	NRG Oncology Foundation	Member
2018 - present	NRG Oncology Executive Committee	Member

CONTRIBUTIONS TO DIVERSITY

CONTRIBUTIONS TO DIVERSITY

As a father of 3 daughters I am acutely aware of the need to provide excellent mentoring and promotion of women to achieve senior leadership positions. I am proud of the fact that I have provided career and research mentorship to many successful women at UCSF at several academic ranks. During the period when I served as Associate Dean for Research and as the Director of a PhD program in the Graduate Division I advocated for and expanded the inclusion and acceptance of minority candidates and women to the program. The results of this can be measured in the increased numbers of minority and women graduates from the program and who have joined the ranks of academia.

TEACHING AND MENTORING

TEACHING SUMMARY

1. Predoctoral education, improvement and innovation:

Since 2003 I have been the course director of Oral Pathology (OP127) in the predoctoral curriculum. In 2004 I completely redesigned the course (now numbered BMS 127) to align its format and content within the new dental school curriculum. The course is a component of the Biomedical Sciences stream utilizing a problem-based structure and interactive informatics. I developed and implemented WebCT interactive learning modules that augment the didactic course material. I designed and assisted implementation of the new Oral Medicine didactic and web-based curriculum. In 2005 my success in educational improvement, innovation and effectiveness was recognized with UCSF School of Dentistry Distinguished Teaching Award.

2. Graduate education, curriculum development and enhancement:

In 2004 I conceived and implemented a novel educational pathway for training in clinical and translational research leading to a 4-year PhD degree. This program run jointly through 3 of the 5 UCSF Schools (Dentistry, Medicine and Graduate) is the first PhD program in clinical and translational sciences at UCSF. It is currently funded by the NIH through a T32 NRSA award mechanism (PI: Jordan RCK). The aim of the program is to provide graduate education to dentists and physicians to the PhD level in clinical and translational sciences. Three streams are offered: 1. molecular pathology; 2. epidemiology and clinical trials; 3. advanced dental sciences. Tracks are available to predoctoral students (DSTP), specialist trainees (MD or DDS) and postdoctoral fellows (MD or DDS). In 2008 I conceived and implemented a new education pathway for dental students providing education to the Master's degree level in clinical and translational research. This 5-year program leads to a combined DDS-Master's in Clinical Research with one year of supplemental full-time study in the School of Medicine in addition to the traditional DDS program. It is currently funded by the NIH through a T32 NRSA award mechanism (PI: Jordan RCK).

In 2012, I conceived, developed and received approval from the Commission of Dental Accreditation to launch a residency training program in Oral & Maxillofacial Pathology at UCSF. This is the first residency in this specialty to be based at UCSF. Closing integrated with other training programs (anatomic pathology, dermatopathology, clinical pathology, oral medicine) this education pathway will train the next leaders in the field of oral & maxillofacial pathology.

I developed an elective in oral & maxillofacial surgical pathology and has been offered each year to anatomic & clinical pathology (AP/CP) residents in the School of Medicine. The rotation includes participation in the biopsy service and direct microscopic teaching of challenging head and neck pathology.

Other Teaching:

2000-now	Head and neck oncology rounds (weekly)
2000-now	Pathology reviews (weekly with 1-2 residents at the microscope)
2001-now (2X per year)	Unknown slide sessions, AP/CP residents, Dept. of Pathology, UCSF
2001-now	OMFS resident rounds. Dept. of OMFS, UCSF (12X per year)

FORMAL TEACHING

	Academic Yr	Course No. & Title	Teaching Contribution	School	Class Size

	Academic Yr	Course No. & Title	Teaching Contribution	School	Class Size
	2001 - present	OP127A	Lecturer	Dentistry	120
	2001 - 2003	OP127B	Lecturer	Dentistry	120
	2001 - 2003	OP127B	Seminar leader	Dentistry	25
	2001 - present	OP208	Lecturer	Dentistry	16
	2001 - present	Oral Surgery	Lecturer	Dentistry	15
	2001 - present	Oral Surgery CPC	Lecturer	Dentistry	15
	2001 - present	Oral Pathology elective for general pathology residents	Instructor to general pathology residents & residents at VA hospital	Medicine	1 at a time
	2001 - present	Unknown slide sessions	Instructor to general pathology residents	Medicine	12
	2001 - present	General pathology seminar series	Lecturer to general pathology residents	Medicine	12
	2002 - 2002	UCSF Continuing Education. JA Regezi and RCK Jordan. Oral Diseases: Recent Advances and Challenges in a Case-Based Format, San Francisco CA, September 13, 2002.	Course co-director	Dentistry	
	2003 - 2005	OP127A	Course director	Dentistry	120
	2003 - 2005	OP127B	Course director	Dentistry	120
	2005 - present	BMS 127*	Course director	Dentistry	120

	Academic Yr	Course No. & Title	Teaching Contribution	School	Class Size
	2006 - 2006	UCSF Continuing Education. RCK Jordan, MA Pogrel, BL Schmidt, DP Cox. Oral Pathology - Clinical-Pathological Conference for oral surgeons, San Francisco, November	Course co-director	Dentistry	100
	2004 - present	UCSF Continuing Education. RCK Jordan and MA Pogrel. Oral Pathology - Clinical-Pathological Conference, Hawaii,	Course co-director	Dentistry	60
	2009 - present	Oral Pathology for surgical pathology residents	Lecturer; 2 lectures to surgical pathology residents	Medicine	30
	2010 - present	Grossing boot camp	Lecturer; 2 lectures on head and neck specimens to 20 surgical pathology residents	Medicine	30
	2013 - present	Oral Pathology for dermatology residents	Lecturer; 1 lecture on oral pathology	Medicine	15

PREDOCTORAL STUDENTS SUPERVISED OR MENTORED

Dates	Name	Program or School	Mentor Type	Role	Current Position
1995 - 1996	Jennifer Kushner	U. Toronto		Supervised summer work	Private Practice, Periodontics
1995 - 1995	Paaladinesh Thavendiranathan	U. Toronto		Supervised summer work	Private practice, Dentistry
1995 - 1995	Zuryati Al-Ghani	U. Cardiff		Supervised summer work	Private practice, Dentistry
1995 - 1995	Dhaarmista Patel	U. Cardiff		Supervised summer work	Private practice, Dentistry

Dates	Name	Program or School	Mentor Type	Role	Current Position
1995 - 1995	Ngoc Bahn	U. Cardiff		Supervised summer work	Private practice, Dentistry
1995 - 1995	Sapna Bhattessa	U. Cardiff		Supervised summer work	Private practice, Dentistry
1998 - 2000	Ali Shahnava	U. Toronto		Supervised summer work	Medical school U. McMaster
1999 - 1999	Sophia Patai	U. London		Supervised summer work	Private practice, Medicine
2000 - 2000	Sofeene Chan	U. Toronto		Supervised summer work	Private practice, Dentistry
2005 - present	Stanley Liu	UCSF		Academic mentor	DDS-PhD student
2006 - 2009	Kyle Jones	UCSF		Rotation supervisor & academic mentor	DDS student
2006 - 2006	Soo Uh	UCSF		Academic mentor	DDS student
2007 - 2008	Annie Chou	UCSF		Research supervisor & academic mentor	DDS student

POSTDOCTORAL FELLOWS AND RESIDENTS MENTORED

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
1995 - 1996	Anna Aleinikov DDS	Resident		Research supervisor	Private practice
1996 - 1997	Lisa Choy DDS	Resident		Research supervisor	Private practice
1997 - 1999	Elizabeth Saunders BSc	MSc		Research supervisor	PhD program U. Ottawa
1998 - 2000	Andre Rousseau DDS	MSc		Research supervisor	Asst. Prof. U. Toronto
1999 - 2000	Antti Makitie DDS PhD	Post-doctoral fellow		Research supervisor	Asst. Prof. U. Helsinki

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2002 - 2003	Joseph Rabban MD MPH	AP/CP resident		Research supervisor	Asst. Clinical Prof. UCSF
2003 - 2004	Thaddeus S. Connelly DDS MD	OMFS resident		Research supervisor	OMFS resident
2003 - 2004	Marcello Bortoluzzi DDS	Post-doctoral researcher		Research supervisor	Asst. Prof. Brazil
2003 - 2004	Trent Westernoff MD DDS	Resident		Research supervisor	US Army OMFS
2003 - 2005	Maricris Macabeo-Ong BS MS	MS		Research supervisor	SRA III, UCSF
2005 - 2006	Aditi Bhattacharya BDS	PhD		Rotation supervisor	PhD student
2006 - 2008	Yoshi Shen DDS	Post-doctoral fellow		Academic mentor	MS program
2007 - 2008	Antonieta Solar MD	Surgical pathology fellow		Clinical supervisor	Faculty, Catholic University of Santiago, Chile
2008 - 2009	Kelly Guggisberg MD	Surgical pathology fellow		Clinical supervisor	Faculty, University of Calgary
2010 - 2010	Jeff North MD	Dermatopathology Fellow		Clinical supervisor	UCSF
2011 - 2011	Iwai Yeh MD	Dermatopathology Fellow		Clinical supervisor	UCSF
2012 - 2012	Panitta Sitthinamsuwan	Dermatopathology Fellow		Clinical supervisor	UCSF

FACULTY MENTORING

Dates	Name	Position while Mentored	Mentor Type	Mentoring Role	Current Position
-------	------	-------------------------	-------------	----------------	------------------

Dates	Name	Position while Mentored	Mentor Type	Mentoring Role	Current Position
2002 - 2015	Caroline Shiboski DDS PhD	Clinical Assistant Professor	Career Mentor	Academic and research collaborator/advisor	Professor & Dept Chair
2007 - 2014	Maria Orellana DDS MSc PhD	Assistant Professor	Career Mentor	Academic and research collaborator/advisor	Assistant Professor
2008 - present	Christine Glastonbury MBBS	Associate Professor	Career Mentor	Academic and research collaborator/advisor	Professor
2010 - present	Jeffry Simko MD PhD	Associate Professor	Research/Scholarly Mentor, Career Mentor	Academic and research collaborator/advisor	Professor
2011 - present	Sue Yom MD PhD	Assistant Professor	Research/Scholarly Mentor, Career Mentor	Mentor	Assistant Professor
2013 - present	Iwei Yeh MD	Assistant Professor	Research/Scholarly Mentor, Career Mentor	Mentor	Associate Professor
2015 - present	Sarah Calkins MD	Assistant Professor	Career Mentor	Mentor	Assistant Professor

RESEARCH AND CREATIVE ACTIVITIES

RESEARCH AND CREATIVE ACTIVITIES SUMMARY

The focus of my research career has been the study of cancers of the head and neck. As an oral/head and neck pathologist with a strong research interest in cancer, I have led and also contributed significantly to a wide range of scientific investigation from biologically based, mechanistic studies that examine the development of oral cancer, lymphoma and salivary gland diseases to epidemiological studies of these and other cancers. Starting as a junior investigator and continuing to today I have successfully developed and led a team focused on the molecular markers that predict the development of cancer including those of the head and neck. This work has been funded through my career by several extramural grants from leading funding bodies including the NIH. Several seminal publications developed from my work established the key molecular events that are needed for the development of oral cancer. Focusing in on the use of patient derived biopsy material to study cancer genetics my team established and published now widely cited methods to quantify DNA and RNA aberrations in material sourced from paraffin embedded tissues. Much of my own research has focused on the role of HPV 16 in head and neck cancer. For example, in 2010 I was part of a team that published the seminal study published in the New England Journal of Medicine that showed the effect of tobacco on survival in HPV-associated head and neck cancer. This paper is now widely cited as a landmark paper establishing the prognostic value of HPV16 and tobacco

status in head and neck cancer. In 2011 I was the lead author of a publication describing a new and more reproducible method to report p16 results for HPV positive head and neck cancer that is now the standard in the conduct of cancer clinical trials. A recent publication this year established the minimal role for HPV16 in oral cavity cancer. increasingly head and neck cancer trials are using this method as the gold standard assessment for p16 scoring in the setting of head and neck cancer.

My own research has been significantly complemented and enhanced in my role as Director, NRG Oncology Biospecimen Bank. Since 2008 I have served as Director of the NRG Oncology Biospecimen Bank (formerly the Radiation Therapy Oncology Group) now with biobanking locations in San Francisco, Houston, Pittsburgh and at the Nationwide Children's Hospital in Columbus Ohio. NRG Oncology was formed in 2014 from the amalgamation of 3 well known and leading legacy cancer trials groups: RTOG, GOG and NSABP and is now the largest of the 5 NCI funded co-operative cancer groups enrolling 5099 patients annually into late stage phase 2 and stage 3 cancer clinical trials. The NRG Biospecimen Bank supports these studies by collecting, storing, reviewing and distributing 138,000 biospecimens (blood, serum, plasma, CSF, tissues, saliva, urine, bronchial washings) per year across the four sites. I am responsible for oversight and leadership of the NRG Oncology Biospecimen Banks including direction and finances of the bank and I am PI of the grants that support its operation. My role as Director and PI also includes membership on many NRG Oncology Steering Committee and the RTOG Foundation Executive. I am also the liaison to NCI Group Banking Committee and sit on the steering committee as Vice Chair. This body formulates and implements policies that govern national biobanking in the setting of clinical cancer trials. Since 2008 I have also directed the oral/head and neck pathology tumor for NRG Oncology. This activity involves administrative oversight and review of pathology specimens for study inclusion and research design. In my leadership role within NRG Oncology I am part of a team of internationally recognized experts in cancer care that develops and leads new cancer clinical trials where radiation therapy is the primary treatment modality. This leadership role permits me to contribute to the development and testing of new cancer therapies that importantly positively impact patient care I serve as pathology study chair for 6 on going large scale multi-institution cancer trials where I review and provide second pathology opinion on several hundred enrolled cases each year.

RESEARCH AWARDS - CURRENT

1. U24CA196067	PI		Jordan (PI)
National Cancer Institute		04/01/2015	03/31/2020
NRG Oncology Biospecimen Bank		\$ 2,131,428 direct/yr 1	\$ 10,754,076 total

NRG Biospecimen Bank (NRG-BB) supports the efforts of NRG Oncology (NRG) through the operational consolidation of the three separate biobanks that served the now merged National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). A distributed organizational model whereby the three legacy sites in Pittsburgh, San Francisco, and Columbus each focus on a sub-set of cancer disease types, taking advantage of their specialized cancer-specific expertise and existing tumor and tissue specimens. The NRG-BB is co-directed by three highly experienced pathologists, each of whom currently holds leadership positions in the legacy biorepositories. The NRG-BB integrate the three banks through a single management system and a common information technology platform. The biobanking services are state-of-the-art, and the investigators have already established an effective automated process for uploading biospecimen data to the NCTN Navigator portal, as well as a robust data and specimen tracking and reporting system (STARS) that will ensure consistency in data management.

2.	U24CA196067 - supplement	PI		Jordan (PI)
	National Cancer Institute		08/01/2015	07/31/2020
	NRG Oncology Biospecimen Bank for NCORP studies		\$ 160,998	\$ 804,990 total
			direct/yr 1	

This is a supplement to the main U24 Biospecimen Bank award that funds the collection, annotation, storage and use for research of specimens collected for patients enrolled in the NCI Community Oncology Research Program.

3.	3U10CA180868	PI		Jordan (PI)
	National Cancer Institute		03/01/2015	02/28/2019
	BIQSFP NRG Oncology Network Group Operations Center		\$ 146,524	\$ 345,850 total
			direct/yr 1	

The University of California, San Francisco is responsible for receiving all specimens from enrolling sites, cataloging and preparing the H&E sections and unstained slides. The University of California, San Francisco will digitize the H&E for central pathology review via the Aperio Scanner. The University of California, San Francisco will coordinate the central pathology review with Dr. Aldape at Princess Margaret Hospital who will provide instruction to the University of California, San Francisco on the preparation of the unstained slides for the MGMT analysis. The University of California, San Francisco will prepare and ship via Priority FedEx the unstained slides to MD Anderson (MDA) Molecular Diagnostic Laboratory (MDL) for MGMT review. The University of California, San Francisco will also pay for the shipping costs of the return of unused DNA from MDA to the University of California, San Francisco for storage. The University of California, San Francisco will work with Dr. Aldape and Dr. Erik Sulman of the MDA MDL on ensure that central pathology is confirmed and MGMT status is conveyed to NRG headquarters for patient stratification and randomization.

4.	U10CA180868	PI	1% % effort	Jordan (PI)
	National Cancer Institute		03/01/2014	02/27/2018

BIQSFP NRG Oncology Network Group Operations \$ 61,750 direct/yr \$ 247,000 total
Center for BN (CNS tumors) 001 1

This is a supplement to the main U24 Biospecimen Bank award that funds the collection, annotation, storage and use for research of specimens collected for patients enrolled in the NCI Community Oncology Research Program.

5.	P30AI027763 (Volberding) Co-I NIH/NIAID Center for AIDS Research (CFAR), UCSF AIDS Specimen Bank	5% % effort 9/1/2017 \$ 2,668,144 direct/yr 1	Volberding (PI) 8/30/2022
----	---	--	------------------------------

The purpose of CFAR is to continue the expansion of translational HIV investigations that bridge the disciplines of basic, clinical, and behavioral sciences. Three scientific priorities have been defined at each potential translational interface through a comprehensive strategic planning process. These priorities include developing new assays and therapies, biological intervention of transmission, and improving adherence and outcome of therapy. Role: Responsible for the support of CFAR investigators by providing specimen repository services.

I am PI of the UCSF AIDS Biospecimen Bank that serves as the repository and distributor of biospecimens used by investigators who conduct research on HIV/AIDS. I participate in the group leadership and the development and implementation of research studies in CFAR.

6.	R01DE026502 Co-Investigator NIDCR Genetic Predictors of Ameloblastoma Behavior	5% % effort 09/01/2017 \$ 511,525 direct/yr 1	Pollack (PI) 08/31/2022 \$ 2,358,0855 total
----	--	--	--

We hypothesize that a new paradigm for the diagnostic classification of ameloblastomas and other aggressive odontogenic tumors can be generated by genomic analysis. A complete genetic understanding of these tumors should yield new biomarkers of tumor behavior, and provide a rational basis for new molecularly-directed treatments. The ultimate goal is to revolutionize the treatment of ameloblastoma and related odontogenic neoplasias, by incorporating new personalized medicine therapies that minimize or eliminate the need for aggressive surgery. Our studies have already initiated a funded pilot clinical trial of dual BRAF/MEK inhibitor neoadjuvant treatment of ameloblastoma at Stanford, the results of which we will leverage in this proposal. To address these goals, our proposal will identify the spectrum of driver mutations within ameloblastomas and morphologically similar odontogenic tumors and correlate these findings with clinical features to generate molecular biomarkers. We will also develop preclinical models for pharmacologic studies on newly-discovered mutations associated with ameloblastoma.

I contributed to generation of preliminary data and the writing of this grant application. I will assist in the pathological review of odontogenic tumors and contribute samples required for genomic analysis (Specific Aim 1). In addition, I will contribute to data analysis, interpretation, presentation of results, and preparation of results for scientific publication

7.	RTOG 3504 PI RTOG Foundation and Bristol Meyers Squibb	2 % effort 08/17/2017	Jordan (PI) 08/16/2020
----	---	--------------------------	---------------------------

Safety Evaluations of Nivolumab (Anti-PD-1) Added to Chemotherapy (CRT) Platforms in Patients with Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma \$ 13,265 direct/yr \$ 39,795 total
1

Funding is provided to support PD-L1 testing for patients enrolled in clinical trial RTOG 3504.

8.	3U10CA180868-04S	PI	2% % effort	Jordan (PI)
	National Cancer Institute		03/01/2017	02/28/2022
	NRG-BN003 Central Pathology & Integrated Biomarker BIQSFP		\$ 4,784.00 direct/yr 1	\$ 32,628.00 total
	Funding to support an integrated biomarker study for NRG-BN003, "Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma." The NRG Oncology Biobank at the University of California, San Francisco (UCSF) will receive all biospecimen materials submitted for NRG-BN003 including the specimens required for the pHH3 analysis. UCSF will prepare and ship the specimens required for the pHH3 analysis in batches at the end of the study. Support will be provided for the central pathology review at UCSF and UCSF's preparation and shipping of the materials.			
9.	RTOGF 3505	PI	effort only % effort	JORDAN (PI)
	RTOG Foundation and Bristol Meyers Squibb		06/05/2018	05/31/2019
	RANDOMIZED, DOUBLE BLINDED PHASE III TRIAL OF CISPLATIN AND ETOPOSIDE PLUS THORACIC RADIATION THERAPY FOLLOWED BY NIVOLUMAB PLACEBO FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER		\$ 30,823 direct/yr 1	\$ 30,823 total
10.	3U10CA180868-05S1	Co-I	1% % effort	Wolmark (PI)
	National Cancer Institute		03/01/2018	02/28/2019
	NRG Oncology Network Group NRG-BN001 BIQSFP		\$ 24,400.00 direct/yr 1	\$ 113,400.00 total

RESEARCH AWARDS - PAST

1.	Principal Investigator		
	Medical Research Council of Canada (Fellowship)	1992	1994
	Molecular detection of early lymphoma in Sjögren's syndrome; PI: Richard C.K. Jordan		\$ 128,625 total

2.	Principal Investigator		
	Medical Research Council of Canada (Fellowship)	1992	1994
	Molecular detection of early lymphoma in Sjögren's syndrome (competitive renewal); PI: Richard C.K. Jordan		\$ 128,625 total
3.	Co-investigator		
	Royal Society of London	1994	1995
	Investigation of gene rearrangements in Sjögren's syndrome; PI: Richard C.K. Jordan & Paul M. Speight		\$ 24,000 total
4.	Co-investigator		
	Royal Society of London STA	1994	1995
	Molecular detection of early lymphoma in Japanese patients with Sjögren's syndrome; PI: Richard C.K. Jordan		\$ 6,200 total
5.	Principal investigator		
	Sunnybrook Trust for Research	1991	1992
	C-erbB-2 expression in salivary gland neoplasms; PI: Richard C.K. Jordan		\$ 42,000 total
6.	Principal investigator		
	Sunnybrook Trust for Research	1995	1996
	Markers of radioresistance in head and neck cancers; PI: Richard C.K. Jordan		\$ 50,000 total
7.	Principal investigator		
	Sunnybrook Trust for Research	1995	1996
	Study of apoptosis and cell proliferation in oral precancer and cancer; PI: Richard C.K. Jordan		\$ 6,000 total
8.	Principal investigator		
	Apotex Pharmaceuticals	1996	1997

Randomized clinical trial of amitriptyline for the treatment of chronic facial pain; PI: Richard C.K. Jordan \$ 2,000 total

9.	Principal investigator		
	Medical Research Council of Canada Summer Research Program	1996	1997
	p53 expression and cell kinetics in oral epithelial dysplasia from the floor of the mouth; PI: Richard C.K. Jordan		\$ 4,250 total

10.	Principal investigator		
	Medical Research Council of Canada Summer Research Program	1996	1997
	Expression of cell cycle regulating proteins in oral carcinoma.; PI: Richard C.K. Jordan		\$ 4,250 total

11. UI-14291	Principal investigator		
	Medical Research Council of Canada	1997	2000
	Prospective analysis of p53 mutations in head and neck cancer; PI: Richard C.K. Jordan		\$ 118,228 total

12.	Principal investigator		
	New Technologies Fund, Sunnybrook & Women's Hospital	1997	1999
	Applications of laser micro-dissection and automated DNA sequencing to molecular pathology; PI: Richard C.K. Jordan		\$ 149,300 total

13.	Principal investigator		
	Medical Research Council of Canada Summer Research Program	1998	1999
	p53 gene mutations in sequential samples of oral dysplasias and carcinomas; PI: Richard C.K. Jordan		\$ 4,250 total

14.	Principal investigator		
	Ontario Ministry of Health (Career Scientist Award)	1998	2000

Molecular markers of oral precancer and cancer; PI: Richard C.K. Jordan (award voluntarily terminated due to relocation to USA) \$ 250,000 total

15. 10216 Co-investigator
National Cancer Institute of Canada 1999 2002
The timing of radiotherapy in head and neck cancer; PI: Georg A. Bjarnason \$ 280,572 total

16. Co-investigator
Radiation Program Research Fund. TSRCC 1999 2000
Prevalence of IRF-1 deletions in head and neck squamous cell carcinomas; PI: John Kim \$ 7,753 total

17. DE13904-01 Co-investigator
National Institute of Dental and Craniofacial Research 2001 2006
Adhesion and proliferation in oral cancer progression. Pilot project no. 1. CDKN2A abnormalities in oral cancer progression.; PI: Randall Kramer \$ 148,789 total

18. AC-05-01 Principal investigator
American Cancer Society 2001 2002
Characterization of novel biomarkers in oral cancer; PI: Richard C.K. Jordan \$ 18,769 total

19. 38107-523981-43000 Principal investigator
Research Evaluation and Allocation Committee, School of Medicine, UCSF. 2001 2002
Prediction of Oral Cancer Progression. New genetic markers; PI: Richard C.K. Jordan \$ 17,564 total

20. R21 CA94216 Co-investigator
National Cancer Institute 2002 2004

Exploratory studies on cancer detection, prognosis and prevention.; PI: David T. Wong			\$ 250,000 total
21. R21CA095231	Principal investigator		
National Cancer Institute		2002	2004
Molecular predictors of oral cancer development; PI: Richard C.K. Jordan			\$ 750,000 total
22.	Principal investigator		
UCSF Academic Senate		2002	2003
Shared equipment grant; PI: Richard C.K. Jordan			\$ 36,000 total
23. 11RT-0141	Principal investigator		
Tobacco-related Diseases Research Program		2002	2006
Molecular predictors of oral cancer development; PI: Richard C.K. Jordan			\$ 420,000 total
24. PO1 DE07946	Collaborator		
National Institutes of Health		2000	2005
Oral manifestations of AIDS; PI: John S. Greenspan			\$ 5,124,000 total
25. U01 DE 15018.	Co-investigator.		
National Institutes of Health		2003	2008
Development of technologies for saliva/oral fluid based diagnostics; PI: David T. Wong			\$ 2,845,679 total
26. 12KT-0166	Co-investigator		
Tobacco-Related Diseases Research Program		2003	2006
Peripheral mechanisms of oral cancer pain in a mouse model; PI: Brian L. Schmidt			\$ 750,000 total

27. RO1 CA095231	Principal investigator		
National Cancer Institute		2004	2009
Molecular predictors of oral cancer development; PI: Richard C.K. Jordan			\$ 1,100,000 total
28.	Co-investigator		
National Institutes of Health		2004	2009
Genomics and Proteomics of Oral Precancer Progression; PI: David T. W. Wong			\$ 1,250,000 total
29.	Co-investigator		
National Institutes of Health.		2006	2010
Prediction of metastasis in oral cancer by genomic profiling; PI: Brian L. Schmidt			\$ 1,893,750 total
30. U54RR023566-01	Co-investigator, Assistant Director Mentor Development Program		
National Institutes of Health		2006	2011
Clinical and Translational Sciences Institute; PI: Clay Johnston			\$ 81,340,569 total
31.	Co-investigator		
Amarillo BioSciences (industry)		2003	2011
Evaluation Of Natural Human Interferon Alpha Administered Oromucosally In The Treatment Of Oral Warts In HIV-Seropositive Subjects Receiving Combination Anti-Retroviral Therapy; PI: D. Greenspan			\$ 20,570 total
32. 38107-523981-43000	Co-investigator		Simko,J (PI)
Research Evaluation and Allocation Committee, School of Medicine, UCSF.		2010	2011
Tissue Microarrayer Construction Device			\$ 20,996 total

33. P0036326	Co-PI		Gillison (PI)
Ventana Medical Systems Inc.		2010	2011
HPV detection in tissues. PI: Maura Gillison (Ohio State University)			\$ 12,000 total
<hr/>			
34. 5U10CA21661	co-PI		Curran/Jordan (PI)
National Cancer Institute		07/01/2013	
Integral Determination of p16 Expression in Oropharyngeal Carcinoma as an Eligibility Criterion and EGFR expression in all Tumors as a Stratification Factor			\$ 172,284 total
<hr/>			
35. U10 CA21661	Co-investigator		
National Institutes of Health		2010	2015
Radiation Therapy Oncology Group, Biospecimen Resource; PI: W. Curran		\$ 50,000 direct/yr 1	
<hr/>			
36. 1T32DE019096-01	Principal investigator		
National Institutes of Health/NIDCR		2008	2013
DDS-Master in Clinical Research (T32)			\$ 1,046,854 total
<hr/>			
37. NO1 DE32636	Co-investigator. Co-director of the tissue and histopathology core.		Criswell, Shiboski (PI)
National Institutes of Health		2004	2015
International Research Registry for Sjögren's syndrome (SICCA); PI: C. Shiboski & L. Criswell			\$ 14,594,672 total
<hr/>			
38. U24 CA1147374	co-PI		Jordan, Roach (PI)
American College of Radiologists		2007	2014
Radiation Therapy Oncology Group, Tissue Bank Project		\$ 915,000 direct/yr 1	\$ 6.3 million total

39. RTOG 10-04447	PI	effort only % effort	JORDAN (PI)
American College of Radiology		12/01/2017	11/30/2018
RTOG 3505: RANDOMIZED, DOUBLE BLINDED PHASE III TRIAL OF CISPLATIN AND ETOPOSIDE PLUS THORACIC RADIATION THERAPY FOLLOWED BY NIVOLUMAB/PLACEBO FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER		\$ 89,608.00 direct/yr 1	\$ 89,608 total
Grant provides funding for biospecimen process, storage and specimen review. Oversee the testing, administration of grant, scoring and review of cases			
40. 1R01DE022565-01A1	co-I	5% % effort	Kramer, R (PI)
NIH		03/15/2013	03/28/2018
Mechanism regulating ErbB signaling network in head and neck cancer		\$ 250,000 direct/yr 1	\$ 1,250,000 total
<p>(provided by applicant): Invasive squamous cell carcinoma is the most common malignant tumor of the upper aerodigestive tract. Despite advances in surgical and radiotherapeutic approaches for therapy, the overall prognosis of oral and head and neck cancer remains poor primarily due to its aggressive invasive capacity, recurrence, and local and distant metastases. Oral squamous cell carcinomas with regional metastasis have a survival rate close to 50%. There is an urgent need to develop novel molecular targets that yield new effective therapeutic approaches. Squamous cell carcinomas present as tightly associated nests of three-dimensional tumor with extensive cell-cell junctional adhesions that permit cell growth and resistance to apoptotic insults. Our findings implicated the involvement of intercellular adhesions in conferring this protection and revealed that cell-cell contacts provide discrete cell survival signaling. The overall goal of this project is to define the mechanisms that regulate growth factor receptor signaling profiles that lead to more aggressive oral SCC cell populations and to identify how complex cellular microenvironmental interrelationships contribute to development of resistance to inhibitors targeting ErbB axis family members. Recent clinical studies have examined the prognostic relevance of overexpressed ErbB3 in HNSCC and report that elevated ErbB3 correlates with metastatic disease and poor overall patient survival. This project focuses specifically on the overriding hypothesis that in oral SCC development, high-density three-dimensional nests of tumor cells promote shifts in specific ErbB family signaling profiles favoring enhanced proliferation and tumor progression. Aim 1 will investigate how the 3D-tumor microenvironment regulates cell growth. Aim 2 will identify the mechanism controlling ErbB receptor profile in tumor foci. Aim 3 will define the importance of HIF-1? induction of ErbB receptor expression in tumor progression. These proposed studies should foster an increased understanding of the evolution of aggressive HNSCC that could be exploited for the future development of novel therapeutic strategies.</p> <p>Review pathology from experimental studies. Contribute specimens and quantify immunohistochemistry,</p>			

PEER REVIEWED PUBLICATIONS

- * denotes RCJ as corresponding author or project leader

2. Edwards L, **Jordan RC**. Introduction. *Semin Cutan Med Surg*. 2015 Dec; 34(4):159-60. PMID: 26814329
3. **Jordan RC**, Kahn HJ, From L, Jambrosic J. Immunohistochemical demonstration of actinic damaged elastic fibers in keratoacanthoma: An aid in diagnosis. *J Cut Pathol* 1991;18:81-86
4. Haas DA, Nakanishi O, MacMillan RE, **Jordan RC**, Hu J. Development of an orofacial model of acute inflammation in the rat. *Arch Oral Biol* 1992;37(5):417-422
5. Main JHP, **Jordan RC**, Barewal R. Facial Neuralgias: A Clinical Review of 33 patients. *J Can Dent Assoc* 1992;58(9):752-755
6. **Jordan RC**, Dardick I, Lui E, Birek C. Demonstration of c-erbB-2 oncogene overexpression in salivary gland neoplasms using in situ hybridisation. *J Oral Med Pathol* 1994;23:226-231
7. Birek C, Lui E, **Jordan RC**, Dardick I. Demonstration of c-erbB-2 amplification in salivary gland neoplasms using the polymerase chain reaction. *Oral Oncol* 1994;30(B):47-50
8. Speight PM, **Jordan RC**, Colloby P, Nandha H, Pringle JH. Light chain restriction in minor salivary glands may predict lymphoma development in Sjogren's syndrome. *Oral Oncol* 1994;30(B):244-247
9. Speight PM, **Jordan RC**, Colloby P, Nandha H, Pringle JH. Light chain restriction detected by in situ hybridisation predicts lymphoma development in patients with Sjogren's syndrome. in: *Sjogren's Syndrome: State of the Art*. Homma M, Sugai S, Tojo T, Miyasaki N, Akizuki M. (eds) Krugler Press, Amsterdam 1994, pp. 529-532
10. **Jordan RC**, Diss TC, Lench NT, Isaacson PG, Speight PM. Immunoglobulin heavy chain rearrangements in labial gland biopsies detected by the polymerase chain reaction. in: *Sjogren's syndrome: State of the Art*. Homma M, Sugai S, Tojo T, Miyasaki N, Akizuki M. (eds) Krugler Press, Amsterdam 1994, pp. 461-464
11. **Jordan RC**, Diss TC, Lench NT, Isaacson PG, Speight PM. Immunoglobulin gene rearrangements in lymphoplasmacytic infiltrates of labial salivary glands in Sjogren's syndrome: A possible predictor of lymphoma development. *Oral Surg Oral Med Oral Pathol* 1995;79:723-729
12. **Jordan RC**, Pringle JH, Speight PM. High frequency of light chain restriction in labial gland biopsies of Sjogren's syndrome detected by in situ hybridisation. *J Pathol* 1995;177:35-40
13. **Jordan RC**, Odell E, Speight PM. B-cell monoclonality in salivary lymphoepithelial lesions of Sjogren's syndrome. *Oral Oncol* 1996;32B:38-44
14. Aleinikov A, **Jordan RC***, Main JHP. Topical steroid therapy in oral lichen planus: a review of therapy in 24 patients. *J Can Dental Assoc* 1996;62(4):241-244
15. **Jordan RC***, Masaki Y, Takeshita S, Speight PM, Sugai S. High prevalence of B-cell monoclonality in labial gland biopsies of Japanese Sjogren's syndrome patients. *Int J Hematol* 1996;64:47-52
16. **Jordan RC***, Catzavelos GC, Barrett AW, Speight PM. Differential expression of bcl-2 and bax in oral squamous cell carcinomas. *Oral Oncol* 1996;32B:394-400
17. **Jordan RC**, Millson C, Wilson M, Speight PM. Absence of *Helicobacter pylori* in salivary lymphoepithelial lesions. *J Oral Pathol Med* 1997; 26: 454-457

18. **Jordan RC***, Chong L, Di Pierdomenico S, Satira F, Main JHP. Oral lymphoma in HIV-infection. *Oral Diseases* 1997;3(1):135-137 [1.445]
19. Yamada K, **Jordan RC**, Mori M, Speight PM. The relationship between E-cadherin expression and tumour differentiation in oral squamous cell carcinoma. *Oral Diseases* 1997;3:82-85
20. Leung C-S, **Jordan RC**. Solitary angiokeratoma of the oral cavity. *Oral Surg Oral Med Oral Pathol.* 1997;84:51-53
21. Pollet A, Perez-Ordenez B, **Jordan RC**, Davidson M J. High grade papillary cystadenocarcinoma of the tongue. *Histopathol.* 1997;31:185-188
22. Kushner J, Bradley G, **Jordan RC***. Patterns of p53 and Ki-67 protein expression in oral epithelial dysplasia from the floor of mouth *J Pathol* 1997;183:418-423
23. **Jordan RC***, Bradley G, P, Slingerland J. Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. *Am J Pathol.* 1998;152:585-590
24. **Jordan RC***, Chong L, Di Pierdomenico S, Satira F, Main JHP. Oral lymphoma in HIV-infection. A report of six cases and review of the literature. *Otolaryngol-H & N Surg* 1998;119(6):672-678
25. Ko K, Dover D, **Jordan RC***. Bilateral dentigerous cysts. Report of an unusual case and review of the literature. *J Can Dent Assoc.* 1999;65(1):49-51
26. Rousseau A, Mock D, Dover DG, **Jordan RC***. Multiple canalicular adenomas. A case report and review of the literature. *Oral Surg Oral Med Oral Pathol.* 1999;87:346-350
27. Kushner J, Bradley G, Young B, **Jordan RC***. Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. *J Oral Pathol Med.* 1999; 28: 77-81
28. Perez-Ordenez B, Koutlas IG, Gilbert RW, **Jordan RC***. Solitary fibrous tumor of the oral cavity. An uncommon location for a ubiquitous neoplasm. *Oral Surg Oral Med Oral Pathol.* 1999;87:589-593
29. Lu Y, Takata T, Mock D, **Jordan RC***. Odontogenic ghost cell carcinoma. Report of four new cases and review of the literature. *J Oral Pathol Med* 1999;28(7):323-329
30. Rousseau A, Perez-Ordenez B, **Jordan RC***. Giant cell angiofibroma of the oral cavity: Report of a new location for a rare tumor. *Oral Surg Oral Med Oral Pathol* 1999;88(5):581-585
31. Bjamason GA, **Jordan RC**, Southern RB. Circadian variation in the expression of the nuclear proteins cyclins A, E, B1 and Ki-67 in human oral epithelium. *Am J Pathol* 1999;154:613-622
32. Allan K, Ang,L-C, **Jordan RC**, Taylor M, Young B. Overexpression of cyclin A and cyclin B1 proteins in astrocytoma. *Arch Pathol Lab Med* 1999;124(2):216-220
33. Saunders E, MacKenzie R, Shipman R, Gilbert R, **Jordan RC***. Patterns of p53 gene mutations in head and neck cancer: Full-length gene sequencing and results of primary radiotherapy. *Clin Cancer Res* 1999;5(9):2455-2463
34. Shahnava SA, Regezi JA, Bradley G, Dube ID, **Jordan RC***. p53 gene mutations in sequential oral epithelial dysplasias and carcinomas. *J Pathol* 2000;190:417-422

35. Shahnava SA, Bradley G, Regezi JA, Thakker N, Gao L, Hogg D, **Jordan RC**. * Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas. *Cancer Res* 2001;61:2371-2375
36. Rousseau A, Lim MS, Lin Z, **Jordan RC***. Frequent cyclin D1 gene amplification in oral epithelial dysplasia. *Oral Oncol* 2001;37:268-275
37. Gstaiger M,** **Jordan RC**,** Lim MS, Catzavelos C, Mestan J, Slingerland JM, Krek W. The F-box protein Skp2 is the product of an oncogene and is overexpressed in human cancers. *Proc Nat Acad Sci USA* 2001;98:5043-5048
38. Bjarnason GA, **Jordan RC**, Wood PA, Lincoln D, Sothorn RB, Ben-David Y. Identification of clock gene expression in human oral epithelium and skin over 24 hours. Correlation with circadian cell cycle progression. *Am J Pathol* 2001;158(5):1793-1801
39. Sanchez-Cespedes M, Parrella P, Nomoto S, Cohen D, Xiao Y, Esteller M, Jeronimo C, **Jordan RC**, Nicol T, Koch WM, Schoenberg M, Mazzarelli P, Fazio VM, Sidransky D. Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. *Cancer Res* 2001;61:7015-7019
40. **Jordan RC***, Glenn L, Treseler P, Regezi JA. Granulocytic sarcoma of the mandible. Report of a case with an unusual presentation and review of the literature. *J Oral Maxillofac Surg* 2002;60:1206-1211
41. Hewitt C, Wu CL, Evcans G, Howell A, Elles RG, **Jordan RC**, Sloan P, Read AP, Thakker N. Germline mutation of ARF in a melanoma kindred. *Hum Mol Genetics* 2002;11(11):1274-1279
42. Regezi JA, Ramos D, Pytela R, Dekker N, **Jordan RC**. Tenascin and beta6 integrin are overexpressed in oral cancer. *Oral Oncol* 2002;38:332-336
43. Regezi JA, **Jordan RC**. Oral Kaposi's sarcoma: Biopsy accessions as an indication of declining incidence. *Oral Surg Oral Med Oral Pathol* 2002;94(4):399
44. Ramos DM, But M, Regezi JA, Schmidt B, Atakilit A, Dang D, Ellis D, **Jordan RC**, Li X. Expression of integrin beta-6 enhances the invasive behavior of oral squamous cell carcinoma. *Matrix Biol* 2002;21:297-307
45. Macabeo-Ong M, Ginzinger DG, Dekker N, McMillan A, Regezi JA, Wong DTW, **Jordan RC***. Effect of formalin fixation time on quantitative RT-PCR expression analysis. *Modern Pathol* 2002;15(9):979-987
46. Lim MS, Adamson A, Lin Z, Perez-Ordóñez B, **Jordan RC**, Tripp S, Perkins SL, Elenitoba-Johnson KSJ. Expression of skp2, a p27kip1 ubiquitin ligase: correlation with p27kip1 and proliferation index in malignant lymphoma. *Blood* 2002;100(8):2950-2956
47. Regezi JA, N. Dekker, Ramos DM, Li X, Macabeo-Ong M, **Jordan RC**. Proliferation and invasion factors in HIV-associated dysplastic and non-dysplastic oral warts, and oral squamous cell carcinoma: an immunohistochemical and RT-PCR evaluation. *Oral Surg Oral Med Oral Pathol* 2002;94:724-731
48. Kim T-W, Chen Q, Shen X, Regezi JA, Ramos DM, Tanaka H, **Jordan RC**, Kramer RH. Oral mucosal carcinogenesis in SENCAR mice. *Anticancer Res* 2002;22:2733-2740
49. Kawara S, Mydlarski R, Mamelak AJ, Freed I, Wang B, Watanabe H, Shivji G, Tavadia SK, Suzuki H, Bjarnason GA, **Jordan RC**, Sauder DN. Low-dose ultraviolet B rays alter the

- mRNA expression of the circadian clock genes in cultured human keratinocytes. *J Invest Dermatol* 2002;119(6):1220-3
50. Pogrel MA, Schmidt BL, Sambajon V, **Jordan RC**. Lingual nerve damage from inferior alveolar nerve blocks: A possible explanation. *J Am Dent Assoc* 2003;134:195-199
 51. **Jordan RC***, Regezi JA. Oral spindle cell neoplasms. A review of 307 cases. *Oral Surg Oral Med Oral Pathol* 2003;95(6):717-724
 52. Brothwell DJ, Lewis DW, Bradley G, Leong I, **Jordan RC**, Mock D, Leake JL. Observer Agreement in the Grading of Oral Epithelial Dysplasia. *Community Dent Oral Epidemiol.* 2003;31(4):300-305
 53. Makitie AA, Chau M, Lim S, Viani M, Gilbert R, Lim MS, **Jordan RC***. Selective Inhibition of Cyclooxygenase-2 Induces p27kip1 and skp2 in Oral Squamous Cell Carcinoma. *J Otolaryngol* 2003;32(4):1-8
 54. Macabeo-Ong, Shiboski CH, Silverman S, Ginzinger DG, Dekker N, Wong DTW, **Jordan RC***. Quantitative analysis of cathepsin L mRNA and protein expression during oral cancer progression. *Oral Oncol* 2003;39:638-647
 55. Rabban JT, Dekker N, **Jordan RCK**. CD10 expression in salivary gland tumors, emphasizing the distinction of primary, clear cell carcinoma from renal cell carcinoma. *Modern Pathol* 2003;16: 221A-222A.
 56. Kennedy MT, **Jordan RC**, Berean KW, Perez-Ordenez B. Expression pattern of CK7, CK20, CDX-2 and villin in intestinal-type sino-nasal adenocarcinoma. *J Clin Pathol.* 2004 Sep;57(9):932-7
 57. Zhou X, **Jordan RC**, Mok S, Birrer MJ, Wong DT. DNA copy number abnormality of oral squamous cell carcinoma detected with cDNA array-based comparative genomic hybridization. *Cancer Genet Cytogenet.* 2004 May;151(1):90-2.
 58. Pogrel MA, **Jordan RC**. Marsupialization as a definitive treatment for odontogenic keratocysts. *J Oral & Maxillofac Surg.* 2004;2:651-655.
 59. Baumgarth N, Szubin R, Dolganov GM, Watnik MR, Greenspan D, Da Costa M, Palefsky JM, **Jordan RC**, Roederer M, Greenspan JS. Highly Tissue Substructure-Specific Effects of Human Papilloma Virus in Mucosa of HIV-Infected Patients Revealed by Laser-Dissection Microscopy-Assisted Gene Expression Profiling. *Am J Pathol* 2004;165(3):707-718
 60. St John MAR, Li, Y, Zhou X, Denny P, Ho C-M, Montemagno C, Shi W, Qi F, Wu B, Sinha U, **Jordan RC**, Wolinsky L, Park N-H, Abermayor E, Wong DTW. II-6 and II-8: Potential biomarkers for oral cancer and oropharyngeal SCC. *Arch Otolaryngol H & N Surg.* 2004;130:929-935
 61. Bortoluzzi MC, Yurgel LS, Dekker NP, **Jordan RC**, Regezi JA, Assessment of p63 expression in oral squamous cell carcinomas and dysplasias. *Oral Surg Oral Med Oral Pathol* 2004;98:698-704
 62. **Jordan RC***, Macabeo-Ong M, Shiboski CH, Ginzinger DG, Wong DTW, Schmidt BL. Overexpression of matrix metalloproteinases-1 and 9 mRNA are associated with progression of oral dysplasia to cancer. *Clin Cancer Res* 2004;10:6460-6465

63. Li Y, St. John MAR, Zhou X, Kim Y, Sinha U, **Jordan RC**, Eisele D, Abemayor E, Elashoff, Wong DTW. Salivary transcriptome diagnostics for oral cancer detection. *Clin Cancer Research* 2004;10(24):8442-8450
64. Perez-Ordenez B, Huynh NN, Berean KW, **Jordan RC**. Expression of mismatch repair proteins, beta catenin, and E cadherin in intestinal-type sinonasal adenocarcinoma. *J Clin Pathol*. 2004 Oct;57(10):1080-1083
65. Kennedy MT, **Jordan RC**, Berean KW, Perez-Ordenez B. Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinoma. *J Clin Pathol*. 2004 Sep;57(9):932-7
66. Westernoff T, **Jordan RC**, Regezi JA, Ramos DM, Schmidt B. Beta 6 integrin, tenascin-C and MMP-1 expression in salivary gland neoplasm. *Oral Oncol* 2005;41:170-174
67. Connelly ST, Macabeo-Ong M, **Jordan RC**, Schmidt BL. Increased nitric oxide levels and iNOS overexpression in oral squamous cell carcinoma. *Oral Oncol* 2005; 41(3):261-267
68. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. *Cancer*. 2005 May 1;103(9):1843-9
69. Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, **Jordan RC**, Albertson DG. Rare amplicons implicate frequent misspecification of cell fate in oral squamous cell carcinoma. *Oncogene* 2005 Jun 16;24(26):4232-4242
70. Zhou X, **Jordan RC**, Yang L, Huang B-L, Wong DTW. Frequent allelic imbalance at 8p and 11q22 in oral cavity and oropharyngeal epithelial dysplastic lesions. *Cancer Genet Cytogenet*. 2005 Aug;161(1):86-89
71. Albertson DG, Snijders AM, Fridlyand J, **Jordan RC**, Pinkel D, Schmidt BL. Genomic analysis of tumors by array comparative genomic hybridization: more is better. *Cancer Res* 2006 Apr 1;66(7):3955-6
72. Cox D, Greenspan JS, Greenspan D, **Jordan RC***. Oral bowenoid papulosis in an HIV-positive male. *Oral Surg Oral Med Oral Pathol* 2006; 102(4):431-432
73. Shiboski CH, Schmidt BL, **Jordan RC**. Racial disparity in stage at diagnosis and survival among adults with oral cancer in the US. *Community Dent Oral Epidemiol* 2007;35:233-240
74. Schmidt BL, Picker, V, Liu S, Quang P, Dolan J, Connelly T, **Jordan RC***. Peripheral endothelin A receptor antagonism attenuates carcinoma induced pain. *Eur J Pain*. 2007;11:406-414
75. Pickering V, **Jordan RC**, Schmidt BL. Elevated salivary endothelin levels in oral cancer patients--a pilot study. *Oral Oncol*. 2007 Jan;43(1):37-41
76. Cox DP, Treseler P, Dong R, **Jordan RC***. Rare oral cavity presentation of a B-cell lymphoblastic lymphoma. A case report and review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2007 Jun;103(6):814-9
77. Viet CT, **Jordan RC**, Schmidt BL. DNA promoter hypermethylation in saliva for the early diagnosis of oral cancer. *J Calif Dent Assoc*. 2007 Dec;35(12):844-9
78. Guerrero AV, Quang P, Dekker N, **Jordan RC**, Schmidt BL. Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. *Neurosci Lett*. 2008 Jan 8

79. Snijders AM, Huey B, Connelly ST, Roy R, **Jordan RC**, Schmidt BL, Albertson DG. Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene. *Oncogene* 2008; 1-13
80. Solar A, Schmidt BL, **Jordan RC***. Hyalinizing Clear Cell Carcinoma: Case Series And Comprehensive Review Of The Literature. *Cancer* 2009;115:75-83
81. Bjarnason GA, Mackenzie RG, Nabid A, Hodson ID, El-Sayed S, Grimard L, Brundage M, Wright J, Hay J, Ganguly P, Leong C, Wilson J, **Jordan RC**, Walker M, Tu D, Parulekar W. Comparison Of Toxicity Associated With Early Morning Versus Late Afternoon Radiotherapy In Patients With Head-And-Neck Cancer: A Prospective Randomized Trial Of The National Cancer Institute Of Canada Clinical Trials Group (HN3). *Int. J. Radiation Oncology Biol. Phys.* 2009 Vol. 73, No. 1pp. 166-172 (editorial for this paper published *Int. J. Radiation Oncology Biol. Phys.*, Vol. 73, No. 1, pp. 3-5, 2009)
82. Chou A, Dekker N, **Jordan RC***. Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2009;107:535-541
83. Feldman, MD, Huan L, Guglielmo BJ, **Jordan RC**, Kahn J, Creasman JM, Wiener-Kronish J, Lee KA, Tehrani A, Yaffe K, Brown JS. Training the Next Generation of Research Mentors: The University of California, San Francisco, Clinical & Translational Science Institute Mentor Development Program. *Clin Transl Sci.* 2009 Jun 1;2(3):216-221.
84. Guggisberg K, **Jordan RC***. Mantle cell lymphoma of the oral cavity: Case series and comprehensive review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2010 Jan;109(1):98-104.
85. Vaderhobli RM, White JM, Le C, Ho S, **Jordan RC**. In vitro study of the soft tissue effects of microsecond-pulsed CO₂ laser parameters during soft tissue incision and sulcular debridement. *Lasers Surg Med.* 2010 Mar;42(3):257-63.
86. Cox DP, Daniels TD, **Jordan RC***. Solitary Fibrous Tumor of the Head and Neck: A comprehensive review of an unusual soft tissue tumor. *Oral Surg Oral Med Oral Pathol* 2010 Jul;110(1):79-84.
87. Jones K, **Jordan RC***. Patterns of second-opinion diagnosis in oral and maxillofacial pathology *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2010
88. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T PF, Westra WH, Chung CH, **Jordan RC**, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human Papillomavirus (HPV) and Survival of Patients with Oropharynx Cancer. *N Engl J Med.* 2010 Jul 1;363(1):24-35
89. Tetsu O, Phuchareon J, Chou A, Cox DP, Eisele DW, **Jordan RC.*** Gene mutations in the c-Kit pathway disrupt MAPK signaling during tumor development in adenoid cystic carcinoma of the salivary glands. *Neoplasia* 2010;12(9):708-717
90. Chung CH, Dignam JJ, Hammond ME, Klimowicz AC, Petrillo SK, Magliocco A, **Jordan RC**, Trotti A, Spencer S, Cooper JS, Le QT, Ang KK. Glioma associated oncogene family zinc finger 1 expression in and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG9003) *J Clin Oncol.*2011 Apr 1;29(10):1326-34
91. Daniels TE, Cox D, Shiboski CH, Schiodt M, Wu A, Lanfranchi H, Umehara H, Zhao Y, Challacombe S, Lam MY, De Souza Y, Schiødt J, Holm H, Bisio PAM, Gandolfo

- MS, Sawaki T, Li M, Zhang W, Varghese-Jacob B, Ibsen P, Keszler A, Kurose N, Nojima T, Odell E, Criswell LA, **Jordan RC**, Greenspan JS. Associations Between Salivary Gland Histopathologic Diagnoses and Phenotypic Features of Sjogren's Syndrome Among 1,726 Registry Participants. *Arthr Rheum* 2011;63(7):2021-2030
92. Solar AA, **Jordan RC***. Soft tissue tumors and common metastases of the oral cavity. *Periodontology* 2000 2011 Oct;57(1):177-97
93. Antonescu CR, Katabi N, Zhang L, Sung YS, Seethala RR, **Jordan RC**, Perez-Ordoñez B, Have C, Asa SL, Leong IT, Bradley G, Klieb H, Weinreb I. EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. *Genes Chromosomes Cancer*. 2011 Jul;50(7):559-70
94. Gilbert J, Murphy B, Dietrich MS, Henry E, **Jordan RC**, Counsell A, Wirth P, Yarbrough WG, Slebos RJ, Chung CH. Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. *Cancer* 2012 Feb 15;118(4):1007-13 PMID 21766301
95. Chung CH, Zhang Q, Hammond EM, Trotti AM, Wang H, Spencer S, Zhang H-Z, Cooper J, **Jordan RC**, Rotman MH, Ang KK. Integrating EGFR Assay with Clinical Parameters Improves Risk Classification for Relapse and Survival in Head and Neck Squamous Cell Carcinoma. *International journal of radiation oncology, biology, physics* 2011 Oct 1;81(2):331-8
96. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Lui L, Lynch CF, Wentzensen N, **Jordan RC**, Altekruze S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus (HPV) and rising oropharyngeal cancer incidence in the United States. *J Clin Oncol* 2011 Nov 10;29(32):4294-30
97. Bhattacharya A, Roy R, Snijders AM, Hamilton G, Paquette J, Tokuyasu T, Bengtsson H, **Jordan RC**, Olshen AB, Pinkel D, Schmidt BL, Albertson DG. Two distinct routes to oral cancer differing in genome instability and risk for cervical node metastasis. *Clin Cancer Res*. 2011 Nov 15;17(22):7024-34
98. Verstraete FJ, Zin BP, Kass PH, Cox DP, **Jordan RC**. Clinical signs and histologic findings in dogs with odontogenic cysts: 41 cases (1995-2010) *J Am Vet Med Assoc*. 2011 Dec 1;239(11):1470-6
99. Van Loon K, Gill RM, McMahon P, Chigurupati R, Siddiqi I, Fox L, Damon L, McCalmont TH, **Jordan RC**, Wolf J. 20q- clonality in a case of oral sweet syndrome and myelodysplasia. *Am J Clin Pathol*. 2012 Feb; 137(2):310-5.
100. **Jordan RC**, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M, Jiang B, Wakely P, Xiao W, Gillison ML. Validation of Methods for Oropharyngeal Cancer HPV Status Determination in US Cooperative Group Trials. *Am J Surg Pathol*. 2012 Jul;36(7):945-954
101. Gillison ML, Zhang Q, **Jordan RC**, Xiao W, Westra WH, Trotti A, Spencer S, Harris J, Chung CH, Ang KK. Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16-Positive and p16-Negative Oropharyngeal Cancer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* 2012 Jun 10;30(17):2102-11

102. Yang F, Liu R, Kramer R, Xiao W, **Jordan RC**, Lam KS. Discovery of specific ligands for oral squamous carcinoma to develop anti-cancer drug loaded precise targeting nanotherapeutics. *J Calif Dent Assoc.* 2012 Dec; 40(12):939-43. PMID: 23362666
103. Kong CS, Cao H, Kwok S, Nguyen CM, **Jordan RC**, Beaudry VG, Attardi LD, Le QT. Loss of the p53/p63 target PERP is an early event in oral carcinogenesis and correlates with higher rate of local relapse. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2013 Jan; 115(1):95-103. PMID: 23217540
104. Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, **Jordan RC**, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Ann Oncol.* 2014 Nov;25(11):2230-6. PMID: 25081901
105. Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, Perez-Ordenez B, **Jordan RC**, Gillison ML. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. *Oral Oncol.* 2013 Jan; 49(1):1-8. PMID: 22841678
106. Chou A, Taylor KE, **Jordan RCK**, Greenspan JS, Daniels TE, Shiboski CH, Criswell LA Association Between Germinal Center Formation in Labial Salivary Gland Biopsies and Predictors of Lymphoma Among Participants of the Sjogren's International Collaborative Clinical Alliance (SICCA). *Arthritis Rheum* 2013; 65: 3328-3332.
107. Nemecek A, Murphy BG, **Jordan RC**, Kass PH, Verstraete FJM. Oral papillary squamous cell carcinoma in twelve dogs. *J Comp Path* 2014; 150:155-161
108. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, **Jordan RC**, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. *J Clin Oncol.* 2014 Sep 20; 32(27):2940-50. PMID: 25154822.
109. Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, **Jordan RC**, Le QT. p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma. *J Clin Oncol.* 2014 Dec 10; 32(35):3930-8. PMID: 25267748.
110. Schulman JM, **Jordan RC**. Oral mucus extravasation phenomenon with myxoglobulosis. *J Cutan Pathol.* 2014 Oct; 41(10):767-70. PMID: 25351286
111. Dawson AL, Schulman JM, **Jordan RC**, North JP. Ossifying fibroma in Buschke-Ollendorff syndrome. *J Cutan Pathol.* 2014 Sep;41(9):740-4. PMID 24917176
112. Harari PM, Harris J, Kies MS, Myers JN, **Jordan RC**, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, Straube W, Zhang Q, Ang K. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. *J Clin Oncol.* 2014 Aug 10;32(23):2486-95. PMID: 25002723
113. Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, **Jordan**

- RC**, Gillison ML, List M, Le QT. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. *J Clin Oncol*. 2014 Dec 1;32(34):3858-66. PMID: 25366680
114. Horvai AE, **Jordan RC**. Fibro-Osseous Lesions of the Craniofacial Bones: β -Catenin Immunohistochemical Analysis and CTNNB1 and APC Mutation Analysis *Head and Neck Pathology* 2-14; s12105-014-0535-7
115. Jones KB and **Jordan RC***. Oral white lesions. *Seminars in Cutaneous Medicine & Surgery*. 2015 Dec; 34(4):161-170 (peer reviewed)
116. Chou A, Schulman JM, Gross AJ, **Jordan RC**, Ramos DM. Gingival pustules and sterile diffuse sclerosing osteomyelitis as a feature of synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2016 May;121(5):e116-22. PMID: 26619759
117. Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, **Jordan RC**, Johnson DE, Grandis JR. Clin Cancer Res. 2017 Jun 15;23(12):3072-3083. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. PMID: 27986750
118. Krings G, Joseph NM, Bean GR, Solomon D, Onodera C, Talevich E, Yeh I, Grenert JP, Hosfield E, Crawford ED, **Jordan RC**, van Zante A, Zaloudek C, Shin SJ, Chen YY. Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. *Mod Pathol*. 2017 Aug; 30(8):1086-1099. PMID: 28548128
119. Ozawa H, Ranaweera RS, Izumchenko E, Makarev E, Zhavoronkov A, Fertig EJ, Howard JD, Markovic A, Bedi A, Ravi R, Perez J, Le QT, Kong CS, **Jordan RC**, Wang H, Kang H, Quon H, Sidransky D, Chung CH. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. *Clin Cancer Res*. 2017 Sep 1;23(17):5162-5175. doi: 10.1158/1078-0432.CCR-16-1686. Epub 2017 May 18. PMID: 28522603
120. Dickson BC, Antonescu CR, Argyris PP, Bilodeau EA, Bullock MJ, Freedman PD, Gnepp DR, **Jordan RC**, Koutlas IG, Lee CH, Leong I, Merzianu M, Purgina BM, Thompson LDR, Wehrli B, Wright JM, Swanson D, Zhang L, Bishop JA. Ectomesenchymal Chondromyxoid Tumor: A Neoplasm Characterized by Recurrent RREB1-MKL2 Fusions. *Am J Surg Pathol*. 2018 Jun 15. doi: 10.1097
121. Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim M-O, **Jordan RC**, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR. Regular non-steroidal anti-inflammatory drug use predicts improved survival for PIK3CA-altered head and neck cancer. *Cancer Discovery* (submitted)
122. Ablain J, Xu M, Rothschild H, **Jordan RC**, Mito JK, Daniels BH, Bell CF, Joseph NM, Wu H, Bastian BC, Zon LI, Yeh I. Rapid zebrafish modeling enhances genomic tumor profiling to identify SPRED1 loss as a melanoma driver. *Science* (Science; under review)
123. Cohen JN, Yeh I, **Jordan RC**, Wolsky RJ, Horvai AE, McCalmont TH, LeBoit PE. *Am J Surg Pathol*. 2018 Jul 13. doi: 10.1097/PAS.0000000000001122. [Epub ahead of print] PMID: 30001233

REVIEW ARTICLES

1. **Jordan RC**, Main JHP. The oral manifestations of HIV infection. *J Can Dent* 1991;57(1):59-61
2. **Jordan RC**, Main JHP. Les manifestations buccales lors de l'infection par le VIH (translation). *L'Information Dentaire* 1991;21:1669-1676
3. Main JHP, **Jordan RC**. Melanotic lesions of the mouth. *J Hosp Dent & Oral Surg.* 1991;3(1):3-9
4. **Jordan RC***. Verrucous carcinoma of the mouth. *J Can Dent Assoc* 1995;61(9):797-801
5. **Jordan RC**, Speight PM. Lymphoma in Sjögren's syndrome: From histopathology to molecular pathology. *Oral Surg Oral Med Oral Pathol* 1996;81:308-320 [1.581]
6. **Jordan RC**. Management of lichen planus. *Dentoscope* 1996; 3(3):7-12
7. **Jordan RC***, Daley T. Oral squamous cell carcinoma: new insights. *J Can Dental Assoc* 1997;63(7):454-460
8. Parulekar W, Mackenzie, R, Bjarnason G, **Jordan RC.*** Scoring of oral mucositis. *Oral Oncol* 1998;34:63-71 [3.123]
9. Regezi JA, **Jordan RC**. Oral Cancer in the Molecular Age. *J California Dental Assoc.* 2001;29(8):578-584
10. Sandor GKB, Carmichael RP, Coraza L, ClokieCML, **Jordan RC**. Genetic mutations in certain head and neck conditions of interest to the dentist. *J Can Dent Assoc* 2001;67(10):577-584
11. Bjarnason GA, **Jordan RC**. Rhythms in human gastrointestinal mucosa and skin. *Chronobiology Int* 2002;19(1):129-140 [2.472]
12. Greenspan D, **Jordan RC**. The white lesion that kills. Aneuploid dysplastic oral leukoplakia. *New Engl J Med* 2004; 350(14):1381-1383 [50.017]
13. Arnout A, **Jordan RC**, Slingerland J. p27 deregulation in breast cancer. Prognostic significance and implications for therapy. *J Mammary Gland Biol Neoplasia.* 2004 Jan;9(1):67-80 [3.625]
14. Perez-Ordóñez B, Beauchemin M, **Jordan RC***. Molecular biology of squamous cell carcinoma of the head and neck. *J Clin Pathol.* 2006 May;59(5):445-53 [2.17]
15. **Jordan RC***, Speight PM. Current concepts of odontogenic tumours. *Diag Histopathol* 2009;15(6)
16. **Jordan RC***, Gillison MG, van Zant A. Oropharyngeal carcinoma: A unique human papillomavirus-associated tumor of the head and neck. *Pathology Case Reviews.* 2011;16(4):1-3
17. van Zant A, **Jordan RC**. Salivary duct carcinoma: Pathologic and clinical features of a diagnostically challenging tumor. *Pathology Case Reviews.* 2011;16:34-42
18. van Zant A, **Jordan RC***. Head and neck pathology. *Pathology case reviews.* 2011; 16(4):139-140

19. Edwards L, **Jordan RC***. Introduction to review edition of *Semin Cut Med Surg* 2015 Dec;34(4):159-60.
20. van Zant A, **Jordan RC***. Detection methods for human papillomavirus (HPV) in head and neck cancers. *Textbook of Oral Cancer - Prevention, Diagnosis and Management*. Saman Warnakulasuriya and John Greenspan editors

BOOKS AND CHAPTERS

1. Speight PM, **Jordan RC**. The molecular pathology of Sjögren's syndrome in: *Molecular Pathology of Autoimmunity*. Isenberg DA, Horsfall AC. (eds). Bios Publications, London UK 1994 pp. 25-42
2. **Jordan RC**, Speight PM. Extra-nodal Non-Hodgkin's Lymphomas of the oral cavity. *Current Topics in Pathology*. Seifert, G. et al. (eds.). Springer Verlag Publications. Berlin 1996 pp. 125-146
3. Feliciani C, **Jordan RC**. Developmental disorders. in : *Color Atlas of Oral Diseases*. Lotti T, Parish L, Rogers R. (eds.) Springer Verlag Publications. Berlin 1999 pp. 31-36
4. Bjarnason GA, **Jordan RC**. Circadian variation of cell proliferation and cell cycle protein expression in man: Clinical implications. In: Meijer S, Guidet S, Philippe M, ed. *Progress in cell cycle research*. New York: Plenum press, 2000; vol 4: 193-206
5. Barrett AW, **Jordan RC**. Chapters 44-48. In: Scully C. ed. *Oxford Handbook Of Dental Preclinical Sciences*. Oxford University Press. Oxford UK, 2003
6. Silverman S, Lee N, Kramer AM, **Jordan RC**. Chapter 5. In: *Oral Cancer 5th ed*. BC Decker. London UK. 2003 pp 81-95
7. **Jordan RC**. Chapter 3 Histology and ultrastructure of the odontogenic keratocyst. In: Pogrel A, Schmidt BL eds. *Oral Surgery Clinics of North America*. Saunders. USA 2004 Vol 15 No. 3. pp 325-335
8. **Jordan RC**. Chapter 13: Diagnosis of periodontal manifestations of systemic diseases. In: *Periodontology 2000*. 2004 Vol 34: pp 1-13
9. Solar AA, **Jordan RC***. Soft tissue tumors and common metastases of the oral cavity. *Periodontol 2000*. 2011 Oct;57(1):177-97
10. Regezi JA, Scuibba J, **Jordan RC**. *Oral Pathology. Clinicopathologic correlations*. 7th edition. W.B. Saunders Co. Philadelphia. 2016
11. **Jordan RC** and Lewis MAO. *Color Handbook of Oral Medicine 2nd edition*, Manson Publishing, London, UK. 2012
12. **Jordan RC**. WHO "Blue Book" *Pathology and Genetics of Head and Neck Tumours*. 2nd edition. The International Agency for Research on Cancer. co-author of Chapters 2, 3, & 8

OTHER PUBLICATIONS

1. **Jordan RC**. MSc. thesis. Demonstration of c-erbB-2 overexpression in salivary gland neoplasms by *in situ* hybridization. Faculty of Dentistry, University of Toronto 1991
2. **Jordan RC**. PhD. thesis. The molecular pathology of Sjögren's syndrome. Applications to the early detection of lymphoma. School of Medicine, University of London 1995

3. **Jordan RC**. Oral Cancer. Proctor & Gamble On-line continuing education course (CE348). (*peer reviewed*)2009

SIGNIFICANT PUBLICATIONS

1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T?n PF, Westra WH, Chung CH, **Jordan RC**, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human Papillomavirus (HPV) and Survival of Patients with Oropharynx Cancer. *N Engl J Med*. 2010 Jul 1;363(1):24-35 [50.017]

Based on the RTOG 0129 cancer trial, this paper established the magnitude of survival benefit for patients with HPV+ oropharyngeal cancer and the effect of smoking on survival in this setting.

2. Chung CH, Zhang Q, Hammond EM, Trotti AM, Wang H, Spencer S, Zhang H-Z, Cooper J, **Jordan RC**, Rotman MH, Ang KK. Integrating EGFR Assay with Clinical Parameters Improves Risk Classification for Relapse and Survival in Head and Neck Squamous Cell Carcinoma. *International Journal of Radiation Oncology, Biology, Physics Int J Radiat Oncol Biol Phys*. 2011 Oct 1;81(2):331-8

This paper established the importance of EGFR assessment to stratify outcome risk in patients with head and neck cancer treated by radiation therapy.

3. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Lui L, Lynch CF, Wentzensen N, **Jordan RC**, Altekruze S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus (HPV) and rising oropharyngeal cancer incidence in the United States. *J Clin Oncol* 2011 Nov 10;29(32):4294-30

This paper showed the changing demographics of HPV infection and its relationship to head and neck cancer. I scored all the cases, reviewed the pathology and participated in the writing of the manuscript.

4. **Jordan RC**, Lingen MW, Perez-Ordóñez B, He X, Pickard R, Koluder M, Jiang B, Wakely P, Xiao W, Gillison ML. Validation of Methods for Oropharyngeal Cancer HPV Status Determination in US Cooperative Group Trials. *Am JSurg Pathol*. 2012 Jul;36(7):945-954

Together with Dr. Gillison I conceived, designed and executed this study. This paper established a method to score p16 staining in head and neck cancer trials that is now used in clinical head and neck cancer trials.

5. Harari PM, Harris J, Kies MS, Myers JN, **Jordan RC**, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, Straube W, Zhang Q, Ang K. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. *J Clin Oncol*. 2014 Aug 10;32(23):2486-95. PMID: 25002723

This paper established the roles of chemoradiotherapy and cetuximab in high risk head and neck cancer paving the way for a followup study RTOG 1216 to investigate the role of paclitaxel in the management of this disease. I contributed and accessed all the cases, stained and scored all the cases, reviewed the pathology and contributed to the manuscript writing.

CONFERENCE ABSTRACTS

1. Jordan RC, Kahn HJ, From L. The inclusion of elastic fibers in keratoacanthoma and squamous cell carcinoma. American Academy of Oral Pathology meeting, San Diego CA., April 1990
2. Jordan RC, Kahn HJ, From L, Jambrosic J. The role of actinically damaged elastic fibers in the evolution of keratoacanthoma. American Academy of Dermatology meeting. Ft. Lauderdale FA. November 1990
3. Haas DA, Nakanishi O, MacMillan RE, Jordan RC, Hu J. Characterization of an orofacial model of acute inflammation in the rat. Clinical Research Society of Toronto Annual Meeting, Toronto, Canada. April 1991
4. Jordan RC, Dardick I, Lui E, Birek C. C-erbB-2 oncogene and salivary gland neoplasms. International Association of Oral Pathologists Congress, Hamburg, Germany. July 1992
5. Speight PM, Jordan RC, Colloby P, Nandha H, Pringle JH. Light chain restriction in minor salivary glands may predict lymphoma development in Sjögren's syndrome. IVth International Symposium on Sjögren's syndrome. Tokyo, Japan. August 1993
6. Jordan RC, Diss TC, Lench N, Isaacson PG, Speight PM. High frequency of heavy chain rearrangements in labial gland biopsies of patients with Sjögren's syndrome using the polymerase chain reaction. IVth International Symposium on Sjögren's syndrome. Tokyo, Japan. August 1993
7. Jordan RC, Diss TC, Lench NT, Isaacson PG, Speight PM. Immunoglobulin gene rearrangements in labial gland biopsies detected by the polymerase chain reaction. British Society of Oral Pathology. London, UK September 1993.
8. Speight PM, Jordan RC. Immunopathology, lymphoproliferation and lymphoma development in Sjögren's syndrome. Royal Society of Medicine. London, UK November 1993
9. Jordan RC, Diss TC, Lench NT, Isaacson PG, Speight PM. Lymphoma development in Sjögren's syndrome. The Second Annual Molecular Pathology Symposium. University College London Medical School. London UK December 1993
10. Jordan RC, Lench NJ, Pedeux R, Speight PM. Molecular characterization of malignant lymphomas arising in Sjögren's syndrome. International Association of Oral Pathology Congress. York, England July 1994
11. Jordan RC, Pringle JH, Speight PM. High frequency of light chain restriction in labial gland biopsies of Sjögren's syndrome by in situ hybridisation. International Association of Oral Pathology Congress. York, England July 1994 *winner of IAOP prize
12. Sutcliffe N, Jordan RC, Speight PM, Isenberg DA. Clinical features do not predict lymphoma development in primary Sjögren's syndrome. Vth International Symposium on Sjögren's syndrome. Noordwijkerhout, The Netherlands, June 1995
13. Sugai S, Jordan RC, Takeshita S, Ogawa Y, Masaki M, Arai T, Speight PM. High risk of malignancy in patients with Sjögren's syndrome. Vth International Symposium on Sjögren's syndrome. Noordwijkerhout, The Netherlands, June 1995
14. Jordan RC, Masaki Y, Takeshita S, Speight PM, Sugai S. High prevalence of B-cell monoclonality in labial salivary glands of Japanese Sjögren's syndrome patients.

International Association for Dental Research. Singapore, July 1995 *winner of IADR Experimental Pathology prize

15. Yamada K, Jordan RC, Speight PM, Mori M. Immunolocalization of E-cadherin in oral squamous cell carcinoma. 4th International Congress on Oral Cancer. Gifu, Japan, September 1995
16. Jordan RC, Catzavelos GC, Barrett AW, Speight PM. Differential expression of bcl-2 and bax in oral squamous cell carcinomas. 19th Eastern Great Lakes Head and Neck Oncology Meeting. Toronto, Canada, November 1995
17. Jordan RC, Catzavelos GC, Barrett AW, Speight PM. Bax and bcl-2 oncoproteins are topographically expressed in squamous cell carcinomas of the oral cavity. International Association of Pathology Meeting. Washington D.C., USA, March 1996
18. Jordan RC, Chong L, Di Pierdomenico S, Satira F, Main JHP. Oral lymphoma in HIV infection: A report of 6 cases. Third International Workshop on the Oral Manifestations of HIV Infection. London UK, May 1996
19. Kushner J, Bradley G, Jordan RC. The expression of p53 and Ki-67 proteins in oral epithelial dysplasia from the floor of mouth. Faculty of Dentistry Research Day, University of Toronto. February 1997 *winner of ADA-Dentsply prize
20. Kushner J, Bradley G, Jordan RC. Patterns of p53 and Ki-67 protein expression in oral epithelial dysplasia from the floor of mouth. International Association for Dental Research. Orlando FA. March 1997
21. Alowami S, Perez-Ordenez B, Gilbert R, Jordan RC. Cell cycle kinetics in adenoid cystic carcinoma of the salivary glands. University of Toronto, Department of Pathology Residents Research Day. May 1997.
22. Bjarnason GA, Jordan RC, Southern RB. The cell cycle and the circadian variation in proliferation in human oral mucosa. International Congress on Chronobiology, Paris, France, September 1997
23. Bahn N, Bhattessa S, Jordan RC, Lewis MAO. Survey of back pain in dentist and dental specialists in Wales and Canada. Research Day, University of Wales, January 1998 *winner of BDA-Colgate Prize
24. Kushner J, Bradley G, Jordan RC. Aberrant expression of cyclin A and cyclin B1 in oral carcinomas. Faculty of Dentistry Research Day, University of Toronto. February 1998 *winner of CDA prize
25. Perez-Ordenez B, Alowami S, Gilbert RW, Jordan RC. Alterations in cell kinetics are associated with grade in adenoid cystic carcinoma. International Association of Pathology Meeting. Boston, USA, March 1998
26. Saunders E, Shipman R, Mackenzie R, Jordan RC. Complete p53 gene analysis in head and neck cancer: Mutation detection in genomic DNA from archival specimens. 89th meeting of the American Association for Cancer Research. (vol. 39, abstract no. 2824) New Orleans, USA, March 1998
27. Bjarnason GA, Jordan RC, Southern RB. Circadian variation in the nuclear expression of the proteins cyclins -A, -E, -B1, p53 and Ki-67 in human oral epithelium. 89th meeting of the American Association for Cancer Research. (vol. 39, abstract no. 1674) New Orleans, USA, March 1998

28. Allen K, Ang LC, Jordan RC, Taylor M, Young B. Aberrant cyclin A and cyclin B1 protein expression in astrocytomas. American Association of Neuropathologists. Minneapolis, USA, June 1998
29. Kushner J, Bradley G, Jordan RC. Aberrant expression of cyclin A and cyclin B1 in oral carcinomas. Royal College of Physicians and Surgeons of Canada Annual Meeting. Toronto, September 1998.
30. Perez-Ordóñez B, Jordan RC. Atypical spindle cell hemangiopericytoma of the oral cavity. A potential diagnostic pitfall. Report of a case in an HIV infected patient. Royal College of Physicians and Surgeons of Canada Annual Meeting. Toronto, September 1998
31. Alowami S, Perez-Ordóñez B, Gilbert RW, Jordan RC. Alterations in cell kinetics are associated with grade in adenoid cystic carcinoma. Royal College of Physicians and Surgeons of Canada Annual Meeting. Toronto, September 1998
32. Sapp M, Jordan RC, Berinstein N, Perez-Ordóñez B. Pulmonary angiocentric T-cell lymphoma complicating Sjogren's syndrome and salivary gland MALT-type lymphoma. Royal College of Physicians and Surgeons of Canada Annual Meeting. Toronto, September 1998
33. Saunders E, MacKenzie R, Shipman R, Gilbert R, Franssen E, Jordan RC. Full length gene sequencing in head and neck cancers and outcome of radiation therapy. Eastern Great Lakes Head and Neck Association. 22nd Annual Meeting. Toronto, November 1998
34. Shahnavaaz SA, Regezi JA, Bradley G, Dubé ID, Jordan RC. p53 gene mutations in sequential oral epithelial dysplasias and carcinomas. Eastern Great Lakes Head and Neck Association. 22nd Annual Meeting. Toronto, November 1998
35. Popat SR, Perez-Ordóñez B, Alowami A, Gilbert RW, Jordan RC. Alterations in cell kinetics are associated with grade in adenoid cystic carcinoma. Eastern Great Lakes Head and Neck Association. 22nd Annual Meeting. Toronto, November 1998
36. Shahnavaaz SA, Regezi JA, Bradley G, Dubé ID, Jordan RC. p53 gene mutations in sequential oral epithelial dysplasias and carcinomas. International Association for Dental Research. Vancouver BC, March 1999 *winner of CADR/ARCD Student Research Award and IADR award
37. Ang LC, Allan K, Jordan RC, Young B. Brain invasion is more common in meningiomas with higher cyclin A expression. American Association of Neuropathologists. Portland Oregon, June 1999
38. Bjarnason GA, Jordan RC, Li, Q, Sothorn RB, Ben-David Y. Expression of clock genes in human oral epithelium over 24 hours. International Congress on Chronobiology. Washington DC, September 1999
39. Shahnavaaz SA, Regezi JA, Bradley G, Thakker N, Jordan RC. CDKN2A gene alterations in sequential oral epithelial dysplasias and carcinomas. Great Lakes Head and Neck 23rd Annual Meeting. Hamilton, November 1999
40. Shahnavaaz SA, Regezi JA, Bradley G, Thakker N, Jordan RC. CDKN2A gene alterations in sequential oral epithelial dysplasias and carcinomas. International Association for Dental Research. Washington DC, April 2000

41. Rousseau A, Jordan RC. Quantitative detection of CCND1 gene amplification by duplex PCR in routinely processed biopsies of oral epithelial dysplasia. International Association for Dental Research. Washington DC, April 2000
42. Bjarnason GA, Lincoln DW, Jordan RC, Hrushesky WJM, Li Q, Ben-David Y, Wood PA. Thymidylate synthase (TS) activity in human oral mucosa has a circadian variation with peak activity in S-phase. American Society of Clinical Oncology, New Orleans, May 2000
43. Perez-Ordóñez B and Jordan RC. Expression of p27kip1 and skp2 in mucoepidermoid carcinomas. United States and Canadian Academy of Pathology Meeting. Atlanta G, April 2001
44. Adamson A, Lin B, Perez-Ordóñez B, Jordan RC, Tripp S, Perkins S, Lim M. Expression of skp2, a p27 ubiquitin ligase in malignant lymphoma: Correlation with p27 and proliferation index. United States and Canadian Academy of Pathology Meeting. Atlanta G, April 2001
45. Jordan RC, Lim MS, Krek W, Slingerland JM. Increased skp2 protein is associated with reduced p27kip1 during the progression from oral epithelial dysplasia to invasive cancer. International Association for Dental Research. Chiba, Japan June 2001
46. Pogrel MA, Schmidt BL, Sambojan V, Jordan RC. Lingual nerve fascicles and damage from inferior alveolar nerve blocks: a possible explanation. American Association of Oral & Maxillofacial Surgery Annual meeting. J Oral Maxillofac Surg 2001;59(Suppl 1), 90. Orlando FL, September 2001
47. Regezi JA, Dekker N, Ramos D, Li X, Jordan RC. Oral dysplastic warts: Beta-6, tenascin and MMP expression. American/International Association for Dental Research. San Diego CA, March 2002
48. Jordan RC. Laser microdissection. Advances and Applications to Molecular Pathology. American/International Association for Dental Research. San Diego CA, March 2002
49. Pogrel MA, Jordan RC. Marsupialization as a definitive treatment for odontogenic keratocysts. American Association of Oral & Maxillofacial Surgery Annual meeting. J Oral Maxillofac Surg 2002;60 (Suppl 1), 67-68. Chicago IL, October 2002
50. Perez-Ordóñez B, Barnard M, Nuynh N, Berean K, Jordan RC. Expression of mismatch repair proteins, beta-catenin, E-cadherin and p53 in intestinal-type sinonasal adenocarcinoma. United States and Canadian Academy of Pathology Annual Meeting. Washington DC. March 2003
51. Connelly TS, Macabeo-Ong M, Jordan RC, Schmidt B. Inducible Nitric Oxide Synthase in Human Oral Cavity Squamous Cell Carcinoma. American and Canadian Association of Oral & Maxillofacial Surgeons Annual Meeting. Journal of Oral and Maxillofacial Surgery, 61 (Suppl 1): 39, 2003 Orlando FL September 2003 * winner 1st place best abstract at meeting
52. Macabeo-Ong MC, Shiboski CH, Schmidt BL, Wong DTW, Jordan RC. MMP-1, 2 and 9 in oral precancers and cancers: Potential Biomarkers of Cancer Development. UCSF School of Dentistry Research Day. March 2004
53. Li Y, St. John MAR, Zhou X, Kim Y, Sinha U, Jordan RC, Eisele D, Abemayor E, Elashoff, Wong DTW. Salivary transcriptome diagnostics for oral cancer detection. American Association for Cancer Research annual meeting. Orlando FL. March 2004

54. Liu S, Connelly ST, Jordan RC, Schmidt B. Peripheral Mechanisms of Oral Cancer Pain. American Dental Association meeting. August 2004, winner 1st place scientific competition
55. Liu S, Connelly ST, Jordan RC, Schmidt B. Peripheral Mechanisms of Oral Cancer Pain. California Dental Association meeting. September 2004, winner 1st place basic science competition
56. Bjarnason GA, MacKenzie R, Hodson I, Nabid A, Grimard LJ, Jordan RC, El-Sayed SM, Hay JH, Tu D, Parulekar WR A randomized prospective phase-III study comparing the acute oral mucositis of morning vs. afternoon radiotherapy (RT) in patients with squamous cell carcinoma of the head and neck (SCCHN). American Society of Clinical Oncology annual meeting. May 2005
57. Kolokythas A, Cox DP, Dekker N, Jordan RC, Schmidt BL. Expression of Nerve Growth Factor and Tyrosine Kinase A receptor in Oral Squamous Cell Carcinoma (: Is there an association with perineural invasion? A pilot study.). American Head and Neck Society annual meeting. August 2006
58. Cox D, Lim S, Horvai A, Jordan RC. USP6 oncogene is expressed in aneurysmal bone cysts of the jaws but not central giant cell granulomas. International Association of Pathologists Annual meeting, Montreal, Canada. Abstract number 693. September 2006
59. Macabeo-Ong M, Jordan RC*, Hardt M, Hall SC, Dixon SE, Fisher SJ, Witkowska HE, Lim S, Schmidt BL. Proteomic discovery of markers of metastatic oral SCC. American Association for Cancer Research Biomarker meeting. Chicago IL. September 2006
60. Lim S, Schmidt BL, Witkowska HE, Macabeo-Ong M, Hardt M, Dixon SE, Hall SC, Fisher SJ, Jordan RC*. Psoriasin (S100 A7) identified as a biomarker in oral squamous cell carcinoma using proteomic discovery. American Association for Cancer Research Biomarker meeting. Chicago IL. September 2006
61. Lim S, Schmidt BL, Witkowska HE, Macabeo-Ong, Hardt M, Hall SC, Dixon SE, Fisher SJ, Jordan RC. Psoriasin (S100A7) Identified as a Biomarker in Oral Squamous Cell Carcinoma Using a Proteomic Approach. UCSF Research Day October 2006
62. Macabeo-Ong MC, Schmidt BL, Fisher SJ, Hall SC, Dixon SE, Johansen EB, Hardt M, Witkowska HE, Lim S, Jordan RC. Analysis of whole saliva for oral cancer candidate biomarker identification using 2D-SDS PAGE and mass spectrometry. UCSF Research Day October 2006
63. Quang PN, Jordan RC, Schmidt, BL. Confirmed Role of Endothelin A Receptors, Not B Receptors, In Carcinoma-induced Pain In A Mouse Cancer Model. UCSF Research Day October 2006
64. Viet CT, Lim S, Jordan RC, Schmidt BL. Who put the Methyl Group in my DNA? Promoter Hypermethylation Quantification in Saliva of Oral Precancer and Cancer Patients. UCSF Research Day October 2006
65. Daniels TE, Greenspan JS, Cox D, Criswell L, DeSouza Y, Dong Y, Greenspan D, Jordan RC, Lanfranchi H, Sack K, Schiødt M, Shiboski C, Shiboski S, Sugai S, Umehara H, Whitcher J, Wu A. SICCA-International Sjögren's Syndrome Registry: Design, Preliminary Findings, Future Directions. International Association for Dental Research. New Orleans LA. April 2007

66. Cox DP, Daniels TE, Greenspan JS, Jordan RC, Chirife A, Du D, Ibsen P, Keszler A, Kurose M, Nojima T, Shiboski S, Xiao J et al. SICCA: Labial Salivary Gland Biopsy - Diagnostic Association Analyses. International Association for Dental Research. New Orleans LA. April 2007
67. Viet CT, Lim S, Jordan RC, Schmidt BL. Who put the Methyl Group in my DNA? Promoter Hypermethylation Quantification in Saliva of Oral Precancer and Cancer Patients. AADR annual meeting March 2007 *winner AADR Hatton prize, predoctoral category
68. Jones K, Lim S, Schmidt BL, Jordan RC. Circadian Clock Protein Per-1 is downregulated in Oral Cancer. UCSF Research Day October 2007.
69. Daniels T, Greenspan JS, Cox DP, Criswell LA, DeSouza Y, Dong Y, Greenspan D, Heidenreich A, Johansen S, Jordan RC et al. Objective measures of Sjogren's syndrome are strongly associated with each other but not with sicca symptoms: Analysis of 736 enrollees in the SICCA international registry and repository. American College of Rheumatology 71st annual meeting. November 2007
70. Cox D, Greenspan J, Jordan R, Shiboski C, Shiboski S, Du D, Xiao J, Keszler A, Chirife A, Ibsen P, Nojima T, Kurose N, Morgan P, Daniels T. Morphologic pattern associations in labial salivary gland biopsies with other components of Sjögren's Syndrome in 945 SICCA participants. International Association of Oral Pathologist/American Academy of Oral & Maxillofacial Pathology meeting. San Francisco June 2008
71. Chou A, Lim S, Jordan RC*, Cox D. Identification of Novel c-kit Gene Mutations in Adenoid Cystic Carcinoma of Salivary Gland. American Association for Dental Research Annual meeting. Dallas, TX, April 2008
72. Connelly S T, Snijders AM, Jordan RC, Schmidt BL, Albertson DG. Development and Progression of Proliferative Verrucous Leukoplakia. 7th Intl Head & Neck Meeting, Toronto, Canada July 2008
73. Chou A, Jordan RC*. Identification of Novel FGFR3 Gene Mutations in Actinic Cheilitis. 86th International Association for Dental Research Annual meeting. Toronto, Canada July 2008
74. Bhattacharya A, Jordan RC, Albertson DG, Schmidt BL. Genomic Markers Of Lymph-Node Metastasis In Oral Squamous Cell Carcinoma. 86th International Association for Dental Research Annual meeting. Toronto, Canada July 2008
75. Shiboski C, Da Costa M, Palefsky J, Jordan RC*. Lack of association between HPV infection and oral tongue carcinoma in young and older adults. 7th International Conference on Head and Neck Cancer, San Francisco CA July 2008
76. Daniels TE, Greenspan JS, Challacombe SJ, Cox DP, Criswell LA, deSouza Y, Dong Y, Greenspan D, Heidenreich A, Hamann S, Jordan RC et al. SICCA-International Sjögren's Syndrome Registry: Two Year Follow-up Analyses and Elucidation of Two Keratoconjunctivitis Sicca Subtypes. American College of Rheumatology annual meeting. San Francisco CA, October 2008
77. Chen JY, Huey B, Jordan RC, Albertson DG, Schmidt BL. Genomic analysis of primary and recurrent tumors in oral squamous cell carcinoma. UCSF Research and Clinical Excellence Day October 2008

78. Bhattacharya A, Snijders AM, Dekker N, Jordan RC, Schmidt BL, Albertson DG. Detection of genomic copy number aberrations in oral dysplasias. UCSF Research and Clinical Excellence Day October 2008
79. Chou A, Dekker N, Jordan RC. Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis. UCSF Research and Clinical Excellence Day October 2008 *2nd place prize
80. Gillison M, Zhang Q, Ang KK, Fu KK, Hammond E, Jordan RC, Trotti A, Spencer S, Rotman M, Chung CH. Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003. American Society of Clinical Oncology annual meeting. Chicago June 2010.
81. Chung C, Dignam J, Hammond ME, Magliocco A, Jordan RC, Trotti A, Spencer S, Cooper J, Le Q, Ang KK. High Gli1 expression is associated with poor survival in head and neck cancer patients treated with radiation therapy (RTOG 9003). American Society of Clinical Oncology annual meeting. Chicago June 2010
82. Antonescu C, Katabi N, Seethala R, Jordan RC, Perez-Ordonez B, Asa S, Leong IT, Bradley G, Klieb H, Weinreb I. A Clinicopathologic And Molecular Study Of Hyalinizing Clear Cell Carcinoma Of Salivary Gland. United States and Canadian Academy of Pathology annual meeting, San Antonio TX March 2011.
83. Garcia J, Barnes EL, Cieply K, Dacic S, Jordan RC, Seethala R. Utility of MAML2 Rearrangement Detection Using Fluorescent in-situ Hybridization to Distinguish Glandular Odontogenic Cyst from Central Mucoepidermoid Carcinoma. United States and Canadian Academy of Pathology annual meeting, San Antonio TX March 2011.
84. Jordan RC, Lingen M, Perez-Ordonez B, He X, Pickard R, Inman A, Koluder M, Jiang B, Xiao W, Gillison M. Predictive value of human papillomavirus (HPV)16 in situ hybridization (ISH) and p16 immunohistochemistry (IHC) for HPV oncogene expression in paraffin-embedded oropharynx cancer squamous cell carcinoma (OPSCC). American Society of Clinical Oncology. Chicago, June 2011
85. Ang KK, Zhang QE, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Schwartz DL, El-Naggar AK, Gillison ML, Jordan RC, List MA, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS; A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). American Society of Clinical Oncology. Chicago, June 2011
86. Chaturvedi A, Engels E, Pfeiffer R, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman M, Sibug-Saber M, Cozen W, Liu L, Lynch C, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg P, Gillison ML. Human papillomavirus (HPV) and rising oropharyngeal cancer incidence and survival in the United States. American Society of Clinical Oncology. Chicago, June 2011
87. Gillison ML, Ferris RL, Zhang Q, Colevas D, Mell LK, Kong C, Jordan RC, Moore K, Truong MT, Kirsch C, Machtay M, Curran Jr. WJ, Le Q-T A randomized phase II study of chemoradiation (CRT) +/- nivolumab (Nivo) with sequential safety evaluations of Nivo +/- lirilumab (Liri) or ipilimumab (Ipi) concomitant with (C)RT in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593). Am Society of Clinical Oncology 2017

88. Ko YC, Ko YC, Zhu C, Zhu S, Vennam S, Jordan RC, Pollack J, West R. Gene Expression Profile Of Ameloblastoma. Oral Surg Oral Med Oral Pathol 2017; 124(3): e204

OTHER CREATIVE ACTIVITIES

1. Jordan RCK. Oral pathology study notes. OP127
Jordan RCK and Regezi JA. University of California San Francisco, Interactive Web-CT modules for oral pathology learning & education (Biomedical Sciences Stream 127)
2. Regezi JA, Sciubba J, Jordan RCK. Oral Pathology Clinical-pathologic correlations. 6th edition 2012. Widely used as dental school syllabus in North America and international institutions

Jordan RCK, Lewis MAO, Color Handbook of Oral Medicine. 2nd edition 2013. Used as dental school syllabus in North America and international institutions

ADDITIONAL RELEVANT INFORMATION

University Service, University of Toronto

Faculty of Dentistry

- 1998 Thesis defense committee (chair): B. Freedman, M.Sc.; School of Graduate Studies, University of Toronto
- 1998 Thesis defense committee (chair). Susette Instrum, Diploma in Orthodontics, Faculty of Dentistry, University of Toronto
- 1999 Thesis examination committee. Daniel Wong. M.Sc. School of Graduate Studies, University of Toronto
- 1999 External examiner, thesis examination committee. Ninos Yacouv. M.Sc. School of Graduate Studies, University of Toronto

Faculty of Medicine

- 1998-1999 Graduate supervisory committee. M. Kahil, M.Sc. Department of Laboratory Medicine and Pathobiology, Faculty of Medicine
- 1998-2000 Graduate supervisory committee. M. Viani, M.Sc. Department of Laboratory Medicine and Pathobiology, Faculty of Medicine
- 2000 External examiner, thesis examination committee, Jeffrey Donovan, M.Sc. Department of Medical Biophysics
- External examiner, thesis examination committee, Tarja Juopperi, M.Sc. Department of Medical Biophysics

Hospital

- 1997-2000 Scientific review panel, Sunnybrook Trust for medical research
- 1998 Member, conflict of interest committee
- 1999 Organizer, Integrative Biomedical Science, Research Day, Sunnybrook & Women's College Health Sciences Centre, January